1,463 results on '"Baeten, Jared M."'
Search Results
2. Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa.
- Author
-
Beesham, Ivana, Milford, Cecilia, Smit, Jenni, Joseph Davey, Dvora L, Baeten, Jared M, Heffron, Renee, Beksinska, Mags, and Mansoor, Leila E
- Subjects
Humans ,HIV Infections ,Anti-HIV Agents ,Ambulatory Care Facilities ,South Africa ,Female ,Pre-Exposure Prophylaxis ,Oral pre-exposure prophylaxis ,Post-trial access and use ,Young women ,Infectious Diseases ,Prevention ,HIV/AIDS ,Clinical Research ,Clinical Trials and Supportive Activities ,Mental Health ,Good Health and Well Being ,Public Health and Health Services ,Public Health - Abstract
BackgroundHIV endpoint-driven clinical trials increasingly provide oral pre-exposure prophylaxis (PrEP) as standard of prevention during the trial, however, among participants desiring to continue using PrEP at trial exit, little is known about post-trial PrEP access and continued use.MethodsWe conducted one-time, semi-structured, face-to-face, in-depth interviews with 13 women from Durban, South Africa, from November to December 2021. We interviewed women who initiated oral PrEP as part of the HIV prevention package during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial, elected to continue using PrEP at study exit, and were given a 3-month PrEP supply and referred to facilities for PrEP refills at the final trial visit. The interview guide probed for barriers and enablers to post-trial PrEP access, and current and future PrEP use. Interviews were audio-recorded and transcribed. Thematic analysis was facilitated using NVivo.ResultsOf the 13 women, six accessed oral PrEP post-trial exit, but five later discontinued. The remaining seven women did not access PrEP. Barriers to post-trial PrEP access and continued use included PrEP facilities having long queues, inconvenient operating hours, and being located far from women's homes. Some women were unable to afford transport costs to collect PrEP. Two women reported visiting their local clinics and requesting PrEP but were informed that PrEP was unavailable at the clinic. Only one woman was still using PrEP at the time of the interview. She reported that the PrEP facility was located close to her home, staff were friendly, and PrEP education and counselling were provided. Most women not on PrEP reported wanting to use it again, particularly if barriers to access could be alleviated and PrEP was easily available at facilities.ConclusionsWe identified several barriers to post-trial PrEP access. Strategies to enhance PrEP access such as a reduction in waiting queues, convenient facility operating hours, and making PrEP more widely available and accessible are needed. It is also worth noting that oral PrEP access has expanded in South Africa from 2018 till now and this could improve access to PrEP for participants exiting trials who desire to continue PrEP.
- Published
- 2023
3. Provider perspectives on service delivery modifications to maintain access to HIV pre‐exposure prophylaxis during the COVID‐19 pandemic: qualitative results from a PrEP implementation project in Kenya
- Author
-
Velloza, Jennifer, Roche, Stephanie D, Owidi, Emmah J, Irungu, Elizabeth M, Dollah, Annabell, Kwach, Benn, Thuo, Nicholas B, Morton, Jennifer F, Mugo, Nelly, Bukusi, Elizabeth A, O'Malley, Gabrielle, Ngure, Kenneth, Baeten, Jared M, Mugwanya, Kenneth K, and Team, for the Partners Scale‐Up Project
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Infectious Diseases ,Health Services ,HIV/AIDS ,Prevention ,Clinical Research ,Infection ,Good Health and Well Being ,Humans ,Female ,Adult ,Male ,HIV Infections ,Pre-Exposure Prophylaxis ,Pandemics ,Kenya ,COVID-19 ,Anti-HIV Agents ,adaptation ,HIV ,pre-exposure prophylaxis ,serodiscordant couples ,Partners Scale-Up Project Team ,Clinical Sciences ,Public Health and Health Services ,Other Medical and Health Sciences ,Clinical sciences ,Epidemiology ,Public health - Abstract
IntroductionHIV pre-exposure prophylaxis (PrEP) is an essential prevention strategy being scaled up for priority populations in Kenya, including for HIV serodiscordant couples. The COVID-19 pandemic posed challenges to PrEP rollout. We conducted a qualitative study of PrEP providers to understand how clinics adjusted PrEP delivery during the COVID-19 pandemic.MethodsSince 2017, the Partners Scale-Up Project has integrated PrEP into 25 HIV clinics in Central and Western Kenya. We conducted qualitative interviews with 40 purposively sampled clinic personnel. We interviewed personnel once during the first pandemic wave (May-Aug 2020) and again after some decline in COVID-19 rates (Nov-Jan 2021). We analysed data using inductive memo-writing and summarized data by themes along the PrEP delivery cascade, guided by the Framework for Reporting Adaptation and Modifications (FRAME).ResultsWe interviewed 27 clinical officers, five nurses, four health records and information officers, and four counsellors from Central (n = 20) and Western (n = 20) Kenya. About half (n = 19) were female, with a median age of 32 (IQR: 29-34) and 2.3 years of experience delivering PrEP (IQR: 2-3). All participants reported clinic changes in PrEP demand creation and service delivery during the pandemic. Modifications occurred during PrEP implementation and sustainment phases, were partly reactive to the pandemic and also facilitated by interim Ministry of Health guidance on PrEP delivery during COVID, and were made by PrEP delivery teams, clients and clinic managers. Commonly reported modifications included dispensing multiple-month PrEP refills, intensifying phone-based client engagement and collaborating with other HIV clinics to ensure that clients with prolonged stays in other regions could continue to access PrEP. Some clinics also adopted practices to streamline visits, such as within clinical-room PrEP dispensing, pre-packing PrEP and task-shifting. Most providers liked these changes and hoped they would continue after the pandemic subsides.ConclusionsCOVID-19 served as a catalyst for PrEP delivery innovations in Kenya. HIV clinics successfully and rapidly adapted their PrEP demand creation, refill and retention strategies to promote PrEP uptake and effective use. These modified implementation strategies highlight opportunities to streamline the delivery of PrEP, as well as other HIV and chronic care services, and strengthen engagement with populations post-pandemic.
- Published
- 2023
4. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results
- Author
-
Barnabas, Ruanne V., Brown, Elizabeth R., Onono, Maricianah A., Bukusi, Elizabeth A., Njoroge, Betty, Winer, Rachel L., Galloway, Denise A., Pinder, Leeya F., Donnell, Deborah, N. Wakhungu, Imelda, Biwott, Charlene, Kimanthi, Syovata, Heller, Kate B., Kanjilal, Diane G., Pacella, Daniel, Morrison, Susan, A. Rechkina, Elena, L. Cherne, Stephen, Schaafsma, Torin T., McClelland, R. Scott, Celum, Connie, Baeten, Jared M., and Mugo, Nelly R.
- Published
- 2023
- Full Text
- View/download PDF
5. Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials.
- Author
-
Garcia-Cremades, Maria, Vučićević, Katarina, Hendrix, Craig W, Jayachandran, Priya, Jarlsberg, Leah, Grant, Robert, Celum, Connie L, Martin, Michael, Baeten, Jared M, Marrazzo, Jeanne, Anderson, Peter, Choopanya, Kachit, Vanichseni, Suphak, Glidden, David V, and Savic, Radojka M
- Subjects
HIV/AIDS ,Clinical Trials and Supportive Activities ,Infectious Diseases ,Prevention ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Female ,Humans ,Male ,Anti-HIV Agents ,Data Analysis ,Emtricitabine ,HIV ,HIV Infections ,Medication Adherence ,Pre-Exposure Prophylaxis ,Tenofovir ,Clinical Trials ,Phase III as Topic ,preexposure prophylaxis ,drug protective plasma concentration ,HIV outcome ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
BackgroundDaily dosing of tenofovir disoproxil fumarate, with or without emtricitabine, has high efficacy in preventing human immunodeficiency virus (HIV) infection when individuals are adherent. The target protective plasma concentration of tenofovir (TFV), however, is not fully understood. The aim of this study is to estimate the protective TFV plasma concentration.MethodsParticipant data from TFV-based daily oral and topical active arms of phase 3 trials (iPrEx, VOICE, and Partners PrEP) were pooled (n = 2950). Individual specific risk scores (low and high risk) of acquiring HIV, based on an earlier placebo analysis, were created. Longitudinal TFV pharmacokinetics (PK), HIV outcome, individual risk scores and the effect of sex at birth data were integrated and analyzed using non-linear mixed effects models.ResultsAround 50% of the individuals were estimated to be adherent, which differed from self-reported adherence (∼90%) and large variation between longitudinal adherence patterns were identified. Following oral administration, the estimated protective TFV trough concentration was substantially higher in high-risk females (45.8 ng/mL) compared with high-risk males (16.1 ng/mL) and to low-risk individuals (∼7.5 ng/mL). Dosing simulations indicated that high-risk women require full adherence to maintain protective levels.ConclusionsUsing the largest PK-HIV outcome database to date, we developed a population adherence-PK-risk-outcome model. Our results indicate that high-risk females need higher levels of plasma TFV to achieve HIV protection compared with males. HIV protection exceeds 90% in all populations if daily adherence is achieved.
- Published
- 2022
6. High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study
- Author
-
Beesham, Ivana, Parikh, Urvi M, Mellors, John W, Davey, Dvora L Joseph, Heffron, Renee, Palanee-Phillips, Thesla, Bosman, Shannon L, Beksinska, Mags, Smit, Jennifer, Ahmed, Khatija, Makkan, Heeran, Selepe, Pearl, Louw, Cheryl, Kotze, Philip, Hofmeyr, G Justus, Singata‐Madliki, Mandisa, Rees, Helen, Baeten, Jared M, and Wallis, Carole
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Antimicrobial Resistance ,Clinical Research ,HIV/AIDS ,Infectious Diseases ,Clinical Trials and Supportive Activities ,Genetics ,Development of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,5.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Adult ,Anti-HIV Agents ,Drug Resistance ,Viral ,Female ,Genotype ,HIV Infections ,HIV Seropositivity ,HIV-1 ,Humans ,Mutation ,Prospective Studies ,Reverse Transcriptase Inhibitors ,South Africa ,Young Adult ,antiretroviral resistance ,women ,pretreatment resistance ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundPretreatment HIV drug resistance (PDR) undermines individual treatment success and threatens the achievement of UNAIDS 95-95-95 targets. In many African countries, limited data are available on PDR as detection of recent HIV infection is uncommon and access to resistance testing is limited. We describe the prevalence of PDR among South African women with recent HIV infection from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial.MethodsHIV-uninfected, sexually active women, aged 18-35 years, and seeking contraception were enrolled in the ECHO Trial at sites in South Africa, from 2015 to 2018. HIV testing was done at trial entry and repeated quarterly. We tested stored plasma samples collected at HIV diagnosis from women who seroconverted during follow-up and had a viral load >1000 copies/mL for antiretroviral resistant mutations using a validated laboratory-developed population genotyping assay, which sequences the full protease and reverse transcriptase regions. Mutation profiles were determined using the Stanford Drug Resistance Database.ResultsWe sequenced 275 samples. The median age was 23 years, and majority (98.9%, n = 272) were infected with HIV-1 subtype C. The prevalence of surveillance drug resistance mutations (SDRMs) was 13.5% (n = 37). Nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations were found in 12.4% of women (n = 34). Few women had NRTI (1.8%, n = 5) and protease inhibitor (1.1%, n = 3) mutations. Five women had multiple NRTI and NNRTI SDRMs.ConclusionsThe high levels of PDR, particularly to NNRTIs, strongly support the recent change to the South African national HIV treatment guidelines to transition to a first-line drug regimen that excludes NNRTIs.
- Published
- 2022
7. Exploring adolescent girls and young women's PrEP‐user profiles: qualitative insights into differentiated PrEP delivery platform selection and engagement in Cape Town, South Africa
- Author
-
Rousseau, Elzette, Sikkema, Kathleen J., Julies, Robin F., Mazer, Katelyn, O'Malley, Gabrielle, Heffron, Renee, Morton, Jennifer F., Johnson, Rachel, Celum, Connie, Baeten, Jared M., and Bekker, Linda‐Gail
- Subjects
HIV testing -- Usage ,Courier services -- Usage ,Health care industry -- Usage -- Social aspects ,Sexually transmitted diseases -- Prevention ,Young women -- Social aspects -- Usage ,Reproductive health -- Usage -- Social aspects ,Teenage girls -- Usage -- Social aspects ,Health care industry ,Health - Abstract
: Introduction: Adolescent girls and young women (AGYW), a priority population for HIV prevention in Africa, show high interest but difficulty in sustained effective use of pre‐exposure prophylaxis (PrEP). With ongoing PrEP scale‐up focused on increasing access, it is important to understand what influences AGYW's choice of PrEP delivery platforms. Methods: The POWER implementation study in Cape Town provided PrEP between 2017 and 2020 to AGYW (16−25 years) from four differentiated delivery platforms: mobile clinic, government facility, courier delivery or community‐based youth club. Healthcare providers at government and mobile clinics provided PrEP (initiation and refills) as part of comprehensive, integrated sexual and reproductive health services. Courier and youth club platforms provided light‐touch PrEP refill services incorporating rapid HIV self‐testing. We conducted in‐depth interviews with a purposive sample of AGYW who had ≥3 months of PrEP‐use and accessed ≥2 PrEP delivery platforms. The thematic analysis explored AGYW's preferences, decision‐making and habits related to PrEP access to inform market segmentation. Results: We interviewed 26 AGYW (median age 20) PrEP‐users between November 2020 and March 2021. AGYW PrEP‐users reported accessing different services with, 24 accessing mobile clinics, 17 courier delivery, 9 government health facilities and 6 youth clubs for their PrEP refills. Qualitative findings highlighted four potential behavioural profiles. The “Social PrEP‐user” preferred PrEP delivery in peer spaces, such as youth clubs or adolescent‐friendly mobile clinics, seeking affirmation and social support for continued PrEP use. The “Convenient PrEP‐user” favoured PrEP delivery at easily accessible locations, providing quick (courier) or integrated contraception‐PrEP refill visits (mobile and government clinic). The “Independent PrEP‐user” preferred PrEP delivery that offered control over delivery times that fit into their schedule, such as the courier service. The “Discreet PrEP‐user” highly valued privacy regarding their PrEP use (courier delivery) and avoided delivery options where unintentional disclosure was evident (youth club). Comfort with HIV self‐testing had minimal influence on PrEP delivery choice. Conclusions: Market segmentation of AGYW characterizes different types of PrEP‐users and has the potential to enhance tailored messaging and campaigns to reach specific segments, with the aim of improving sustained PrEP use and HIV prevention benefits., INTRODUCTION The past 5 years have seen the global inclusion of oral pre‐exposure prophylaxis (PrEP) into national guidelines as a key biomedical HIV prevention method, with many countries planning to [...]
- Published
- 2024
- Full Text
- View/download PDF
8. Population-Level Correlation Between Incidence of Curable Sexually Transmitted Infections and Human Immunodeficiency Virus (HIV)-1 Among African Women Participating in HIV-1 Pre-Exposure Prophylaxis Trials.
- Author
-
Hunidzarira, Portia, Brown, Elizabeth R, Chirenje, Z Mike, Hillier, Sharon L, Marrazzo, Jeanne M, Palanee-Phillips, Thesla, Kiweewa, Flavia M, and Baeten, Jared M
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Clinical Sciences ,Health Sciences ,Medical Microbiology ,Mental Health ,Clinical Trials and Supportive Activities ,HIV/AIDS ,Clinical Research ,Infectious Diseases ,Prevention ,Sexually Transmitted Infections ,2.2 Factors relating to the physical environment ,Aetiology ,Infection ,Good Health and Well Being ,Chlamydia Infections ,Chlamydia trachomatis ,Female ,HIV Infections ,HIV-1 ,Humans ,Incidence ,Neisseria gonorrhoeae ,Pre-Exposure Prophylaxis ,Prevalence ,Sexually Transmitted Diseases ,clinical trial design ,HIV incidence ,sexually transmitted infections ,women ,MTN-003/VOICE and MTN-020/ASPIRE Study Teams ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Biological sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundHighly efficacious oral pre-exposure prophylaxis (PrEP) is the global standard for human immunodeficiency virus (HIV)-1 prevention, including in clinical trials of novel PrEP agents using active-comparator designs. The analysis assessed whether incident sexually transmitted infections (STIs) can serve as a surrogate indicator of HIV-1 incidence that might occur in the absence of PrEP.MethodsWe analyzed data from 3256 women randomized to placebo groups of oral and vaginal PrEP trials (MTN-003/VOICE and MTN-020/ASPIRE). Regression modeling assessed the correlation between incident individual STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis, each considered separately) and incident HIV-1.ResultsAcross 18 sites in 4 countries (Malawi, South Africa, Uganda, Zimbabwe), STI and HIV-1 incidences were high: HIV-1 4.9, N gonorrhoeae 5.3, C trachomatis 14.5, and T vaginalis 7.1 per 100 person-years. There was limited correlation between HIV-1 incidence and incidence of individual STIs: N gonorrhoeae (r = 0.02, P = .871), C trachomatis (r = 0.49, P =
- Published
- 2022
9. Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial
- Author
-
Beesham, Ivana, Mansoor, Leila E, Davey, Dvora L Joseph, Palanee-Phillips, Thesla, Smit, Jenni, Ahmed, Khatija, Selepe, Pearl, Louw, Cheryl, Singata-Madliki, Mandisa, Kotze, Philip, Heffron, Renee, Parikh, Urvi M, Wiesner, Lubbe, Rees, Helen, Baeten, Jared M, and Beksinska, Mags
- Subjects
Public Health ,Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Clinical Research ,Prevention ,Sexually Transmitted Infections ,Clinical Trials and Supportive Activities ,Infectious Diseases ,HIV/AIDS ,Contraception/Reproduction ,Infection ,Good Health and Well Being ,Acquired Immunodeficiency Syndrome ,Adolescent ,Adult ,Anti-HIV Agents ,Female ,HIV Infections ,Humans ,Medication Adherence ,Pre-Exposure Prophylaxis ,South Africa ,Tenofovir ,Young Adult ,HIV prevention ,women ,plasma tenofovir ,oral PrEP ,clinical trials ,Africa ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundHIV endpoint-driven clinical trials provide oral pre-exposure prophylaxis (PrEP) as HIV prevention standard of care. We evaluated quantifiable plasma tenofovir among South African women who used oral PrEP during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial.MethodsECHO, a randomized trial conducted in 4 African countries between 2015 and 2018, assessed HIV incidence among HIV-uninfected women, aged 16-35 years, randomized to 1 of 3 contraceptives. Oral PrEP was offered onsite as part of the HIV prevention package at the South African trial sites. We measured tenofovir in plasma samples collected at the final trial visit among women reporting ongoing PrEP use. We used bivariate and multivariate logistical regression to assess demographic and sexual risk factors associated with plasma tenofovir quantification.ResultsOf 260 women included, 52% were ≤24 years and 22% had Chlamydia trachomatis at enrollment. At PrEP initiation, 68% reported inconsistent/nonuse of condoms. The median duration of PrEP use was 90 days (IQR: 83-104). Tenofovir was quantified in 36% (n = 94) of samples. Women >24 years had twice the odds of having tenofovir quantified vs younger women (OR = 2.12; 95% confidence interval = 1.27 to 3.56). Women who reported inconsistent/nonuse of condoms had lower odds of tenofovir quantification (age-adjusted OR = 0.47; 95% confidence interval = 0.26 to 0.83).ConclusionsOver a third of women initiating PrEP and reporting ongoing use at the final trial visit had evidence of recent drug exposure. Clinical trials may serve as an entry point for PrEP initiation among women at substantial risk for HIV infection with referral to local facilities for ongoing access at trial end.Clinical trial numberNCT02550067.
- Published
- 2022
10. Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.
- Author
-
Garcia-Cremades, Maria, Hendrix, Craig W, Jayachandran, Priya, Strydom, Natasha, Jarlsberg, Leah, Grant, Robert, Celum, Connie L, Martin, Michael, Baeten, Jared M, Marrazzo, Jeanne, Anderson, Peter, Choopanya, Kachit, Vanichseni, Suphak, Glidden, David V, and Savic, Radojka M
- Subjects
HIV prevention trials ,key and vulnerable populations ,modeling ,risk factors ,risk phenotypes ,Clinical Research ,Clinical Trials and Supportive Activities ,HIV/AIDS ,Prevention ,Infectious Diseases ,Sexual and Gender Minorities (SGM/LGBT*) ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Pharmacology and Pharmaceutical Sciences - Abstract
The World Health Organization recommends pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV infection. The aim of this analysis is to quantify the individual risk of HIV infection over time, using a large database of high-risk individuals (n = 5583). We used data from placebo recipients in five phase III PrEP trials: iPrEx, conducted in men who have sex with men and transgender women; VOICE, conducted in young women at high sexual risk; Partners PrEP, conducted in HIV serodiscordant heterosexual couples; TDF2, conducted in high-risk heterosexual men and women; and BTS, conducted in persons who inject drugs. The probability of HIV infection over time was estimated using NONMEM7.4. We identified predictors of HIV risk and found a substantial difference in the risk of infection among and within trial populations, with each study including a mix of low, moderate, and high-risk individuals (p < 0.05). Persons who were female at birth were at a higher risk of HIV infection than people who were male at birth. Final models were integrated in a tool that can assess person-specific risk and simulate cumulative HIV risk over time. These models can be used to optimize future PrEP clinical trials by identifying potential participants at highest risk.
- Published
- 2022
11. Peer PrEP referral + HIV self-test delivery for PrEP initiation among young Kenyan women: study protocol for a hybrid cluster-randomized controlled trial
- Author
-
Wairimu, Njeri, Malen, Rachel C., Reedy, Adriana M., Mogere, Peter, Njeru, Irene, Culquichicón, Carlos, McGowan, Maureen, Gao, Fei, Baeten, Jared M., Ngure, Kenneth, and Ortblad, Katrina F.
- Published
- 2023
- Full Text
- View/download PDF
12. Copper intrauterine device increases vaginal concentrations of inflammatory anaerobes and depletes lactobacilli compared to hormonal options in a randomized trial
- Author
-
Brown, Bryan P., Feng, Colin, Tanko, Ramla F., Jaumdally, Shameem Z., Bunjun, Rubina, Dabee, Smritee, Happel, Anna-Ursula, Gasper, Melanie, Nyangahu, Donald D., Onono, Maricianah, Nair, Gonasagrie, Palanee-Phillips, Thesla, Scoville, Caitlin W., Heller, Kate, Baeten, Jared M., Bosinger, Steven E., Burgener, Adam, Passmore, Jo-Ann S., Heffron, Renee, and Jaspan, Heather B.
- Published
- 2023
- Full Text
- View/download PDF
13. Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization
- Author
-
Liu, Gui, Mugo, Nelly R, Brown, Elizabeth R, Mgodi, Nyaradzo M, Chirenje, Zvavahera M, Marrazzo, Jeanne M, Winer, Rachel L, Mansoor, Leila, Palanee-Phillips, Thesla, Siva, Samantha S, Naidoo, Logashvari, Jeenarain, Nitesha, Gaffoor, Zakir, Nair, Gonasagrie L, Selepe, Pearl, Nakabiito, Clemensia, Mkhize, Baningi, Mirembe, Brenda Gati, Taljaard, Marthinette, Panchia, Ravindre, Baeten, Jared M, Balkus, Jennifer E, Hladik, Florian, Celum, Connie L, and Barnabas, Ruanne V
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Sexually Transmitted Infections ,Infectious Diseases ,Cancer ,Cervical Cancer ,Prevention ,Immunization ,HIV/AIDS ,Adolescent Sexual Activity ,Clinical Research ,HPV and/or Cervical Cancer Vaccines ,Vaccine Related ,Pediatric ,Prevention of disease and conditions ,and promotion of well-being ,3.4 Vaccines ,Infection ,Good Health and Well Being ,Adult ,Alphapapillomavirus ,Case-Control Studies ,Female ,HIV Infections ,Humans ,Papillomaviridae ,Papillomavirus Infections ,Papillomavirus Vaccines ,Prevalence ,Risk Factors ,Vaccination ,Young Adult ,adolescent girls and young women ,cervical cancer ,HIV acquisition ,human papillomavirus ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectiveVaccine-preventable human papillomavirus (HPV) infection is common, especially in sub-Saharan Africa where HIV risk is also high. However, unlike other sexually transmitted infections (STIs), HPV's role in HIV acquisition is unclear. We evaluated this relationship using data from MTN-003, a clinical trial of HIV chemoprophylaxis among cisgender women in sub-Saharan Africa.DesignA case-control study.MethodsWe matched 138 women who acquired HIV (cases) to 412 HIV-negative controls. Cervicovaginal swabs collected within 6 months before HIV seroconversion were tested for HPV DNA. We estimated the associations between carcinogenic (high-risk) and low-risk HPV types and types targeted by HPV vaccines and HIV acquisition, using conditional logistic regression models adjusted for time-varying sexual behaviors and other STIs.ResultsMean age was 23 (±4) years. Any, high-risk and low-risk HPV was detected in 84, 74 and 66% of cases, and 65, 55 and 48% of controls. Infection with at least two HPV types was common in cases (67%) and controls (49%), as was infection with nonavalent vaccine-targeted types (60 and 42%). HIV acquisition increased with any [adjusted odds ratio (aOR) 2.5, 95% confidence interval (95% CI) 1.3-4.7], high-risk (aOR 2.6, 95% CI 1.5-4.6) and low-risk (aOR 1.8, 95% CI 1.1-2.9) HPV. Each additional type detected increased HIV risk by 20% (aOR 1.2, 95% CI 1.1-1.4). HIV acquisition was associated with HPV types targeted by the nonavalent (aOR 2.1, 95% CI 1.3-3.6) and quadrivalent vaccines (aOR 1.9, 95% CI 1.1-3.2).ConclusionHPV infection is associated with HIV acquisition in sub-Saharan African women. In addition to preventing HPV-associated cancers, increasing HPV vaccination coverage could potentially reduce HIV incidence.
- Published
- 2022
14. Provider–client rapport in pre-exposure prophylaxis delivery : a qualitative analysis of provider and client experiences of an implementation science project in Kenya
- Author
-
Omollo, Victor, Roche, Stephanie D., Mogaka, Felix, Odoyo, Josephine, Barnabee, Gena, Bukusi, Elizabeth A., Katz, Ariana W. K., Morton, Jennifer, Johnson, Rachel, Baeten, Jared M., Celum, Connie, and O’Malley, Gabrielle
- Published
- 2022
15. Effect of differentiated direct‐to‐pharmacy PrEP refill visits supported with client HIV self‐testing on clinic visit time and early PrEP continuation
- Author
-
Zewdie, Kidist Belay, Ngure, Kenneth, Mwangi, Margaret, Mwangi, Dominic, Maina, Simon, Etyang, Lydia, Maina, Gakuo, Ogello, Vallery, Owidi, Emmah, Mugo, Nelly R., Baeten, Jared M., and Mugwanya, Kenneth K.
- Subjects
Self-examination, Medical -- Methods ,Patient compliance -- Evaluation ,HIV infection -- Prevention ,Health - Abstract
: Introduction: Delivery of oral pre‐exposure prophylaxis (PrEP) is being scaled up in Africa, but clinic‐level barriers including lengthy clinic visits may threaten client continuation on PrEP. Methods: Between January 2020 and January 2022, we conducted a quasi‐experimental evaluation of differentiated direct‐to‐pharmacy PrEP refill visits at four public health HIV clinics in Kenya. Two clinics implemented the intervention package, which included direct‐to‐pharmacy for PrEP refill, client HIV self‐testing (HIVST), client navigator, and pharmacist‐led rapid risk assessment and dispensing. Two other clinics with comparable size and client volume served as contemporaneous controls with the usual clinic flow. PrEP continuation was evaluated by visit attendance and pharmacy refill records, and time and motion studies were conducted to determine time spent in the clinics. Dried blood spots were collected to test for tenofovir‐diphosphate (TFV‐DP) at random visits. We used logistic regression to assess the intervention effect on PrEP continuation and the Wilcoxon rank sum test to assess the effect on clinic time. Results: Overall, 746 clients were enrolled, 366 at control clinics (76 during pre‐implementation and 290 during implementation phase), and 380 at direct‐to‐pharmacy clinics (116 during pre‐implementation and 264 during implementation phase). Prior to implementation, the intervention and control clinics were comparable on client characteristics (female: 51% vs. 47%; median age: 33 vs. 33 years) and PrEP continuation (35% vs. 37% at 1 month, and 37% vs. 39% at 3 months). The intervention reduced total time spent at the clinic by 35% (median of 51 minutes at control vs. 33 minutes at intervention clinics; p Conclusions: A client‐centred PrEP delivery approach with direct‐to‐pharmacy PrEP refill visits plus client HIVST significantly reduced clinic visit time by more than one‐third and improved PrEP continuation in public health HIV clinics in Kenya., INTRODUCTION Oral pre‐exposure prophylaxis (PrEP) is a highly effective HIV prevention strategy [1–3]; however, maximizing access and continuation is a key challenge for optimizing the overall public health impact of [...]
- Published
- 2024
- Full Text
- View/download PDF
16. My Way: development and preliminary evaluation of a novel delivery system for PrEP and other sexual health needs of young women in Western Kenya
- Author
-
Haberer, Jessica E., Oware, Kevin, Juma, Lawrence, Nyerere, Bernard, Momanyi, Vincent, Odoyo, Josephine, Garrison, Lindsey, Bhagat, Julita, Musinguzi, Nicholas, Baeten, Jared M., Siegler, Aaron, and Bukusi, Elizabeth A.
- Subjects
Antiviral agents -- Distribution ,Women's health services -- Management ,HIV infection -- Prevention ,Company business management ,Company distribution practices ,Health - Abstract
: Introduction: Young women in sub‐Saharan Africa are a priority population for HIV prevention, yet challenges with adherence and persistence to HIV pre‐exposure prophylaxis (PrEP) are common. This study involved the development and pilot testing of My Way—a novel delivery system for PrEP and co‐packaged sexual health services. Methods: My Way was developed in Kisumu, Kenya through a user‐centred design process (2020). The intervention involves peer‐delivery and support for HIV testing and PrEP use, self‐collected vaginal swabs for sexually transmitted infection (STI) testing, pregnancy testing, oral contraceptive pills, self‐injectable medroxyprogesterone and/or condoms. My Way was assessed among 16‐ to 24‐year‐old sexually active women in a randomized controlled trial versus standard of care (SoC; 2021–2022). Use of PrEP and other sexual health services were tracked at 1, 3 and 6 months for feasibility. Acceptability was determined by questionnaire. The effect of the intervention on tenofovir diphosphate (TFV‐DP) levels was assessed by chi‐square test (primary outcome); other predictors were explored with regression analysis. Results: Among 150 women, the median age was 22 years and the median number of sexual partners was 2. Moderate/severe depression was common (60%). In the intervention arm, peers made 88% (198/225) of possible kit deliveries (177 with PrEP) and 49 STIs were diagnosed. In the SoC arm, 24% (55/225) of expected clinic visits occurred (53 with PrEP); no STI testing was performed. TVF‐DP was detected in 16 participants at 6 months: 16% (12/75) in the intervention arm versus 5% (4/75) in the SoC arm (p = 0.03). Persistence among those with ongoing HIV prevention needs (i.e. prevention‐effective persistence) was 18% (12/67) versus 7% (4/56; p = 0.08). No women acquired HIV. The intervention was significantly associated with detectable TFV‐DP (OR 3.5, 1.1‐11.4; p = 0.04); moderate/severe depression trended towards an association with TFV‐DP (OR 0.2, 0.03–1.6; p = 0.13). Conclusions: My Way is a promising delivery system for PrEP and other sexual health services among young women in Western Kenya. We found high feasibility and acceptability. PrEP use was modest, but higher with My Way compared to SoC. Long‐acting PrEP formulations may overcome important barriers to PrEP use and should be explored in combination with the My Way delivery model., INTRODUCTION Young women in sub‐Saharan Africa (sSA) are a priority population for HIV prevention, accounting for 63% of all new cases in 2021 [1]. Approximately six of seven new HIV [...]
- Published
- 2024
- Full Text
- View/download PDF
17. CD101 genetic variants modify regulatory and conventional T cell phenotypes and functions.
- Author
-
Richert-Spuhler, Laura E, Mar, Corinne M, Shinde, Paurvi, Wu, Feinan, Hong, Ting, Greene, Evan, Hou, Sharon, Thomas, Katherine, Gottardo, Raphael, Mugo, Nelly, de Bruyn, Guy, Celum, Connie, Baeten, Jared M, Lingappa, Jairam R, Lund, Jennifer M, Partners in Prevention HSV/HIV Transmission Study, and and the Partners PrEP Study Teams
- Subjects
Partners in Prevention HSV/HIV Transmission Study ,and the Partners PrEP Study Teams ,CD101 ,HIV acquisition ,T cell ,host genetic variation ,immune quiescence ,inflammation ,inflammatory homeostasis - Abstract
We recently reported that the risk of sexually acquired HIV-1 infection is increased significantly by variants in the gene encoding CD101, a protein thought to modify inflammatory responses. Using blood samples from individuals with and without these variants, we demonstrate that CD101 variants modify the prevalence of circulating inflammatory cell types and show that CD101 variants are associated with increased proinflammatory cytokine production by circulating T cells. One category of CD101 variants is associated with a reduced capacity of regulatory T cells to suppress T cell cytokine production, resulting in a reduction in the baseline level of immune quiescence. These data are supported by transcriptomics data revealing alterations in the intrinsic regulation of antiviral pathways and HIV resistance genes in individuals with CD101 variants. Our data support the hypothesis that CD101 contributes to homeostatic regulation of bystander inflammation, with CD101 variants altering heterosexual HIV-1 acquisition by facilitating increased prevalence and altered function of T cell subsets.
- Published
- 2021
18. Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial
- Author
-
Glidden, David V, Das, Moupali, Dunn, David T, Ebrahimi, Ramin, Zhao, Yongwu, Stirrup, Oliver T, Baeten, Jared M, and Anderson, Peter L
- Subjects
HIV/AIDS ,Sexual and Gender Minorities (SGM/LGBT*) ,Prevention ,Clinical Trials and Supportive Activities ,Infectious Diseases ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Anti-HIV Agents ,Bayes Theorem ,Emtricitabine ,Female ,HIV Infections ,Homosexuality ,Male ,Humans ,Male ,Pre-Exposure Prophylaxis ,Sexual and Gender Minorities ,Tenofovir ,counterfactual ,PrEP ,clinical trial design ,tenofovir alafenamide ,tenofovir disoproxil fumarate ,Bayesian inference ,Clinical Sciences ,Public Health and Health Services ,Other Medical and Health Sciences - Abstract
IntroductionRandomized trials of new agents for HIV pre-exposure prophylaxis (PrEP) compare against emtricitabine and tenofovir disoproxil fumarate (F/TDF), without a placebo group. We used the well-characterized adherence-efficacy relationship for F/TDF to back-calculate the (non-PrEP) counterfactual background HIV incidence (bHIV) in a randomized trial of a novel PrEP agent and estimate comparative efficacy (to counterfactual bHIV).MethodsThe DISCOVER trial (ClinicalTrials.gov: NCT02842086) randomized 5387 men who have sex with men (MSM) and transgender women who have sex with men and demonstrated non-inferiority of emtricitabine and tenofovir alafenamide (F/TAF) to F/TDF (HIV incidence rate ratio [IRR] 0·47, 95% CI: 0·19 to 1.15). Tenofovir diphosphate (TFV-DP) levels in dried blood spots (DBS) were assessed for all diagnosed with HIV and in a random 10% of the cohort. We used a Bayesian model with a diffuse prior distribution, derived from established data relating tenofovir diphosphate levels to HIV prevention efficacy. This prior, combined with the F/TDF seroconversion rate and tenofovir diphosphate levels in DISCOVER, yielded Bayesian inferences on the counterfactual bHIV.ResultsThere were six versus 11 postbaseline HIV infections (0.14 vs. 0.25/100 person-years [PY]) on F/TAF and F/TDF respectively. Of the 11 on F/TDF, 10 had low, none had medium and one had high tenofovir diphosphate levels; among HIV-negative controls, 5% of the person-time years had low, 9% had medium and 86% had high TFV-DP levels. A non-informative prior distribution for counterfactual bHIV, combined with the prior for TFV-DP level-efficacy relationship, yielded a posterior counterfactual bHIV of 3·4 infections/100 PY (0.80 Bayesian credible interval [CrI] 1·9 to 5·9), which suggests a median HIV efficacy of 96% (0.95 CrI [88% to 99%]) for F/TAF and 93% (0.95 CrI [87% to 96%]) for F/TDF compared to bHIV.ConclusionsBased on the established connection of drug concentrations to PrEP prevention efficacy, a Bayesian framework can be used to estimate a synthetic non-PrEP control group in randomized, active-controlled PrEP trials that include a F/TDF-comparator group.
- Published
- 2021
19. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- Author
-
Barnabas, Ruanne V, Brown, Elizabeth R, Bershteyn, Anna, Stankiewicz Karita, Helen C, Johnston, Christine, Thorpe, Lorna E, Kottkamp, Angelica, Neuzil, Kathleen M, Laufer, Miriam K, Deming, Meagan, Paasche-Orlow, Michael K, Kissinger, Patricia J, Luk, Alfred, Paolino, Kristopher, Landovitz, Raphael J, Hoffman, Risa, Schaafsma, Torin T, Krows, Meighan L, Thomas, Katherine K, Morrison, Susan, Haugen, Harald S, Kidoguchi, Lara, Wener, Mark, Greninger, Alexander L, Huang, Meei-Li, Jerome, Keith R, Wald, Anna, Celum, Connie, Chu, Helen Y, and Baeten, Jared M
- Subjects
Clinical Trials and Supportive Activities ,Clinical Research ,Vaccine Related ,Pneumonia ,Emerging Infectious Diseases ,Prevention ,Lung ,Infectious Diseases ,Infection ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antiviral Agents ,COVID-19 ,COVID-19 Nucleic Acid Testing ,Double-Blind Method ,Female ,Humans ,Hydroxychloroquine ,Male ,Middle Aged ,Post-Exposure Prophylaxis ,SARS-CoV-2 ,Time Factors ,Treatment Outcome ,United States ,Young Adult ,COVID-19 Drug Treatment ,Hydroxychloroquine COVID-19 PEP Study Team ,Clinical Sciences ,Public Health and Health Services - Abstract
BackgroundEffective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies. Laboratory and observational data suggested that hydroxychloroquine had biological activity against SARS-CoV-2, potentially permitting its use for prevention.ObjectiveTo test hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection.DesignHousehold-randomized, double-blind, controlled trial of hydroxychloroquine postexposure prophylaxis. (ClinicalTrials.gov: NCT04328961).SettingNational U.S. multicenter study.ParticipantsClose contacts recently exposed ( 0.20). The frequency of participants experiencing adverse events was higher in the hydroxychloroquine group than the control group (66 [16.2%] versus 46 [10.9%], respectively; P = 0.026).LimitationThe delay between exposure, and then baseline testing and the first dose of hydroxychloroquine or ascorbic acid, was a median of 2 days.ConclusionThis rigorous randomized controlled trial among persons with recent exposure excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection.Primary funding sourceBill & Melinda Gates Foundation.
- Published
- 2021
20. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
- Author
-
Baeten, Jared M, Palanee-Phillips, Thesla, Mgodi, Nyaradzo M, Mayo, Ashley J, Szydlo, Daniel W, Ramjee, Gita, Mirembe, Brenda Gati, Mhlanga, Felix, Hunidzarira, Portia, Mansoor, Leila E, Siva, Samantha, Govender, Vaneshree, Makanani, Bonus, Naidoo, Logashvari, Singh, Nishanta, Nair, Gonasagrie, Chinula, Lameck, Parikh, Urvi M, Mellors, John W, Balán, Iván C, Ngure, Kenneth, van der Straten, Ariane, Scheckter, Rachel, Garcia, Morgan, Peda, Melissa, Patterson, Karen, Livant, Edward, Bunge, Katherine, Singh, Devika, Jacobson, Cindy, Jiao, Yuqing, Hendrix, Craig W, Chirenje, Zvavahera M, Nakabiito, Clemensia, Taha, Taha E, Jones, Judith, Torjesen, Kristine, Nel, Annalene, Rosenberg, Zeda, Soto-Torres, Lydia E, Hillier, Sharon L, Brown, Elizabeth R, Aanyu, Dorothy, Abima, John, Abullarade, Janne, Agarwal, Priyanka, Ahluwalia, Surabhi, Akasiima, Simon Africa, Akello, Carolyne Agwau, Albert, Samuel, Alphale, Motsamai, Alphonse, Calins, Apeduno, Lucy, Aranda, Sara, Aridor, Orly, Arnolds, Shakeera, Asiimwe, Prossy, Atujuna, Millicent, Atwebembere, Didas, Baboolall, Lakshmi, Badana, Kiran, Balamusani, David, Banda, Gabriel, Banda, Towera Whitney, Baugh, Jennifer, Baziira, James Amos, Beamer, May, Bebeza, Sivuyisiwe Asanda, Bekker, Linda-Gail, Bell, Ian, Bemer, Meagan, Berman, Richard, Berthiaume, Jennifer, Bezak, Linda, Bhagwandin, Yashveer, Bhayat, Hassen Anwar, Bhengu, Nokulunga, Bhengu, Sonto, Bhoola, Aruna, Biira, Florence Asiimwe, Bittoni, Daniel, Black, Roberta, Blose, Nombuso Jacqueline, Boks, Pearl, Bolton, Stephen Gordon, Botya, Phathiswa, Brown, Amanda, Brown, Elizabeth, Brown, Helen, Bruce, Robyn Helen, Bukenya, Luke Erismus, Bukirwa, Aidah, Bunts, Lisa, Buthelezi, Fezile, Buthelezi, Mbongeleni William, Buthelezi, Samkelisiwe Dumisile, and Byogero, Rose
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Prevention ,HIV/AIDS ,Mental Health ,Infectious Diseases ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Administration ,Intravaginal ,Adult ,Anti-HIV Agents ,Contraceptive Devices ,Female ,Female ,HIV Infections ,HIV-1 ,Humans ,Malawi ,Patient Compliance ,Patient Safety ,Pyrimidines ,Seroconversion ,South Africa ,Tenofovir ,Treatment Outcome ,Uganda ,Zimbabwe ,MTN-025/HOPE Study Team ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundTwo phase 3 clinical trials showed that use of a monthly vaginal ring containing 25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by approximately 30% compared with placebo. We aimed to evaluate use and safety of the dapivirine vaginal ring (DVR) in open-label settings with high background rates of HIV-1 infection, an important step for future implementation.MethodsWe did a phase 3B open-label extension trial of the DVR (MTN-025/HIV Open-label Prevention Extension [HOPE]). Women who were HIV-1-negative and had participated in the MTN-020/ASPIRE phase 3 trial were offered 12 months of access to the DVR at 14 clinical research centres in Malawi, South Africa, Uganda, and Zimbabwe. At each visit (monthly for 3 months, then once every 3 months), women chose whether or not to accept the offer of the ring. Used, returned rings were tested for residual amounts of dapivirine as a surrogate marker for adherence. HIV-1 serological testing was done at each visit. Dapivirine amounts in returned rings and HIV-1 incidence were compared with data from the ASPIRE trial, and safety was assessed. This study is registered with ClinicalTrials.gov, NCT02858037.FindingsBetween July 16, 2016, and Oct 10, 2018, of 1756 women assessed for eligibility, 1456 were enrolled and participated in the study. Median age was 31 years (IQR 27-37). At baseline, 1342 (92·2%) women chose to take the DVR; ring acceptance was more than 79% at each visit up until 12 months and 936 (73·2%) of 1279 chose to take the ring at all visits. 12 530 (89·3%) of 14 034 returned rings had residual dapivirine amounts consistent with some use during the previous month (>0·9 mg released) and the mean dapivirine amount released was greater than in the ASPIRE trial (by 0·21 mg; p
- Published
- 2021
21. Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection
- Author
-
Stalter, Randy M, Baeten, Jared M, Donnell, Deborah, Spinelli, Matthew A, Glidden, David V, Rodrigues, Warren C, Wang, Guohong, Vincent, Michael, Mugo, Nelly, Mujugira, Andrew, Marzinke, Mark, Hendrix, Craig, Gandhi, Monica, Celum, Connie, Coombs, Robert W, Lingappa, Jairam R, McElrath, M Juliana, Fife, Kenneth H, Were, Edwin, Tumwesigye, Elioda, Ndase, Patrick, Katabira, Elly, Ronald, Allan, Bukusi, Elizabeth, Cohen, Craig R, Wangisi, Jonathan, Campbell, James D, Tappero, Jordan W, Kiarie, James, Farquhar, Carey, John-Stewart, Grace, Mugo, Nelly R, and Ngure, Kenneth
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Trials and Supportive Activities ,Infectious Diseases ,HIV/AIDS ,Sexually Transmitted Infections ,Prevention ,Clinical Research ,Infection ,Good Health and Well Being ,Anti-HIV Agents ,Emtricitabine ,HIV ,HIV Infections ,Humans ,Immunoassay ,Medication Adherence ,Pre-Exposure Prophylaxis ,Tenofovir ,PrEP ,HIV prevention ,urine ,immunoassay ,ELISA ,Partners PrEP Study Team ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
New tools are needed to support PrEP adherence for individuals at risk for HIV, including those that enable provision of real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured by a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir.
- Published
- 2021
22. Brief Report: Bacterial Vaginosis and Risk of HIV Infection in the Context of CD101 Gene Variation
- Author
-
Wanga, Valentine, Mackelprang, Romel D, Thomas, Katherine K, Donnell, Deborah, Cohen, Craig R, Mugo, Nelly R, Bukusi, Elizabeth A, de Bruyn, Guy, Irungu, Elizabeth, Celum, Connie, Baeten, Jared M, and Lingappa, Jairam R
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Prevention ,Clinical Research ,Infectious Diseases ,Genetics ,HIV/AIDS ,Infection ,Adult ,Africa South of the Sahara ,Antigens ,CD ,Coinfection ,Female ,Genetic Predisposition to Disease ,Genetic Variation ,HIV Infections ,Humans ,Longitudinal Studies ,Male ,Membrane Glycoproteins ,Risk Factors ,Vaginosis ,Bacterial ,Young Adult ,BV ,CD101 ,inflammation ,HIV ,Partners in Prevention HSV/HIV Transmission Study and the Partners PrEP Study ,Clinical Sciences ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundWhether bacterial vaginosis (BV) and CD101 immunoglobulin-like (Ig-like) variants independently increase HIV risk through mucosal inflammation is not well understood. We evaluated whether the impact of BV on HIV acquisition in women differs by the presence or absence of candidate CD101 Ig-like variants.MethodsWe used data from 2 studies of HIV serodiscordant couples in east (Kenya, Tanzania, and Uganda) and southern (Botswana, South Africa, and Zambia) Africa, which longitudinally assessed HIV acquisition (by ELISA) and BV (by Nugent score ≥7). We used previously generated CD101 sequence data for each case and control participant to create a binary variable indicating the presence/absence of any of 5 CD101 Ig-like variants.ResultsConfirming previously shown results in this cohort, Ig-like variants increased HIV-infection risk (adjusted hazard ratio [aHR], = 2.63; 95% confidence interval [CI], 1.41 to 4.89). BV was associated with 2.5-fold higher HIV-infection risk only in the absence of Ig-like variants (aHR = 2.47; 95% CI, 0.99 to 6.15; P = 0.052), whereas in the presence of Ig-like variants, BV was not associated with higher HIV-infection risk (aHR = 0.87; 95% CI, 0.35 to 2.15; P = 0.765); however, a test for interaction was nonsignificant (P = 0.116).ConclusionsWe hypothesized that both BV and CD101 Ig-like variants facilitate HIV acquisition by augmenting similar genital inflammation pathways. Our findings indicate that inflammatory mucosal effects of Ig-like variants may influence the impact of BV on HIV risk. Host-defined inflammatory pathways may be useful targets for HIV prevention.
- Published
- 2020
23. Vaginal epithelial dysfunction is mediated by the microbiome, metabolome, and mTOR signaling
- Author
-
Berard, Alicia R., Brubaker, Douglas K., Birse, Kenzie, Lamont, Alana, Mackelprang, Romel D., Noël-Romas, Laura, Perner, Michelle, Hou, Xuanlin, Irungu, Elizabeth, Mugo, Nelly, Knodel, Samantha, Muwonge, Timothy R., Katabira, Elly, Hughes, Sean M., Levy, Claire, Calienes, Fernanda L., Lauffenburger, Douglas A., Baeten, Jared M., Celum, Connie, Hladik, Florian, Lingappa, Jairam, and Burgener, Adam D.
- Published
- 2023
- Full Text
- View/download PDF
24. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
- Author
-
Sax, Paul E., Arribas, José R., Orkin, Chloe, Lazzarin, Adriano, Pozniak, Anton, DeJesus, Edwin, Maggiolo, Franco, Stellbrink, Hans-Jürgen, Yazdanpanah, Yazdan, Acosta, Rima, Huang, Hailin, Hindman, Jason T., Martin, Hal, Baeten, Jared M., and Wohl, David
- Published
- 2023
- Full Text
- View/download PDF
25. Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework
- Author
-
Pintye, Jillian, Davey, Dvora L Joseph, Wagner, Anjuli D, John-Stewart, Grace, Baggaley, Rachel, Bekker, Linda-Gail, Celum, Connie, Chi, Benjamin H, Coates, Thomas J, Groves, Allison K, Haberer, Jessica E, Heffron, Renee, Kinuthia, John, Matthews, Lynn T, McIntyre, James A, Moodley, Dhayendre, Mofenson, Lynne M, Mugo, Nelly, Mujugira, Andrew, Myer, Landon, Shoptaw, Steven, Stranix-Chibanda, Lynda, Baeten, Jared M, and Group, for the PrEP in Pregnancy Working
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Behavioral and Social Science ,Infectious Diseases ,Prevention ,Pediatric AIDS ,Clinical Research ,Pediatric ,HIV/AIDS ,Infection ,Reproductive health and childbirth ,Good Health and Well Being ,Anti-HIV Agents ,Female ,HIV Infections ,Health Plan Implementation ,Humans ,Infectious Disease Transmission ,Vertical ,Male ,Postnatal Care ,Pre-Exposure Prophylaxis ,Pregnancy ,PrEP in Pregnancy Working Group ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
Pregnancy is a high-risk period for HIV acquisition in African women, and pregnant women who become acutely infected with HIV account for up to a third of vertical HIV transmission cases in African settings. To protect women and eliminate vertical transmission, WHO recommends offering oral pre-exposure prophylaxis (PrEP) based on tenofovir to HIV-negative pregnant and post-partum women with a substantial risk of HIV acquisition. PrEP implementation for pregnant and post-partum women lags behind implementation for other high-risk populations. Unique considerations for PrEP implementation arise during pregnancy and post partum, including the integration of provider training with clinical delivery and monitoring of PrEP exposure and outcomes within existing maternal health systems, yet scarce implementation data are available to generate evidence in this context.
- Published
- 2020
26. Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations.
- Author
-
Spinelli, Matthew A, Rodrigues, Warren C, Wang, Guohong, Vincent, Michael, Glidden, David V, Okochi, Hideaki, Stalter, Randy, Defechereux, Patricia, Deutsch, Madeline, Grant, Robert M, Ngure, Kenneth, Mugo, Nelly R, Baeten, Jared M, and Gandhi, Monica
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,Adult ,Anti-HIV Agents ,Antibodies ,Drug Combinations ,Drug Monitoring ,Emtricitabine ,Enzyme-Linked Immunosorbent Assay ,Female ,HIV Infections ,Humans ,Kenya ,Laboratories ,Male ,Patient Compliance ,Point-of-Care Testing ,Sensitivity and Specificity ,Tenofovir ,Uganda ,pre-exposure prophylaxis ,point-of-care ,adherence ,real-time ,antiretroviral therapy ,Partners PrEP Study Team ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundTherapeutic drug monitoring measures antiretroviral adherence more accurately than self-report but has not been available at the point-of-care (POC) until now. We compare a novel POC test for urine tenofovir to laboratory-based enzyme-linked immunosorbent assay (ELISA) testing in diverse patient populations urine pre-exposure prophylaxis (PrEP).SettingUrine samples were analyzed using ELISA and the POC lateral flow immunoassay (LFA) test from 2 cohorts of PrEP users taking tenofovir disoproxil fumarate/emtricitabine: the Partners PrEP Study, which recruited Kenyan and Ugandan heterosexual men and women, and the IBrEATHe Study, which recruited US transgender women and men using gender-affirming hormone therapy.MethodsWe calculated the sensitivity, specificity, and accuracy of the POC test compared with ELISA at a cutoff of 1500 ng/mL.ResultsOverall, 684 urine samples were tested from 324 participants in the 2 cohorts. In Partners PrEP, 454 samples from 278 participants (41% women) were tested with a median age of 33 years. In IBrEATHe, 231 samples from 46 individuals (50% transwomen) were tested with a median age of 31 years. Comparison of the LFA read-out to ELISA yielded 100% sensitivity [97.5% one-sided confidence interval (CI) = 99.3%], 98.3% specificity (95% CI = 95.2% to 99.7%), and 99.6% accuracy (95% CI = 98.7% to 99.9%).ConclusionThe sensitivity, specificity, and accuracy of a novel POC test for urine tenofovir all exceeded 98% when compared with a laboratory-based ELISA method when tested in diverse patient populations. Given the LFA's high accuracy and expected low cost, this POC test is a promising tool to support antiretroviral adherence that could be widely scalable to real-world clinical settings.
- Published
- 2020
27. Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study)
- Author
-
Drain, Paul K, Kubiak, Rachel W, Siriprakaisil, Oraphan, Klinbuayaem, Virat, Quame-Amaglo, Justice, Sukrakanchana, Pra-Ornsuda, Tanasri, Suriyan, Punyati, Pimpinun, Sirirungsi, Wasna, Cressey, Ratchada, Bacchetti, Peter, Okochi, Hideaki, Baeten, Jared M, Gandhi, Monica, and Cressey, Tim R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Infectious Diseases ,Clinical Trials and Supportive Activities ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Adult ,Anti-HIV Agents ,Emtricitabine ,HIV Infections ,Humans ,Male ,Pharmaceutical Preparations ,Plasma ,Pre-Exposure Prophylaxis ,Tenofovir ,HIV ,preexposure prophylaxis ,antiretroviral treatment ,tenofovir ,directly observed therapy ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
BackgroundDirect measurement of tenofovir (TFV) in urine could be an objective measure to monitor adherence to preexposure prophylaxis (PrEP) or TFV-based antiretroviral therapy (ART).MethodsWe conducted a 3-arm randomized, pharmacokinetic study of tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg among adults living with human immunodeficiency virus. Participants were randomized to receive controlled TDF/FTC dosing as (1) "perfect" adherence (daily); (2) "moderate" adherence (4 doses/week); or (3) "low" adherence (2 doses/week). We obtained trough spot urine and plasma samples during a 6-week directly observed therapy period and a 4-week washout period. TFV concentrations were compared between adherence arms using 1-way analysis of variance.ResultsAmong 28 participants, the median age was 33 years and 16 (57%) were male. Correlation between TFV plasma and urine concentrations was strong (ρ = 0.78; P < .0001). Median (interquartile range) steady-state trough TFV concentrations (ng/mL) for perfect, moderate, and low TDF adherence were 41 (26-52), 16 (14-19), and 4 (3-5) in plasma; and 6480 (3940-14 300), 3405 (2210-5020), and 448 (228-675) in urine. Trough TFV concentrations at steady state were significantly different between the 3 adherence arms for plasma (P < .0001) and urine (P = .0002). Following drug cessation, TFV concentrations persisted longer in urine than plasma samples. Washout urine TFV concentrations and time to undetectable concentrations did not differ between the 3 randomized adherence groups.ConclusionsUrine TFV concentrations can inform interpretation of novel point-of-care urine-based TFV assays to assess recent TDF adherence.Clinical trials registrationNCT03012607
- Published
- 2020
28. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
- Author
-
Reddy, Krishnaveni, Kelly, Cliff, Brown, Elizabeth R, Jeenarain, Nitesha, Naidoo, Logashvari, Siva, Samantha, Bekker, Linda-Gail, Nair, Gonasagrie, Makanani, Bonus, Chinula, Lameck, Mgodi, Nyaradzo, Chirenje, Zvavahera, Kiweewa, Flavia Matovu, Marrazzo, Jeanne, Bunge, Katherine, Soto-Torres, Lydia, Piper, Jeanna, Baeten, Jared M, and Palanee-Phillips, Thesla
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Topical Microbicides ,Prevention ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Anti-HIV Agents ,Contraceptive Devices ,Female ,Double-Blind Method ,Female ,HIV Infections ,HIV Seropositivity ,HIV-1 ,Humans ,Pyrimidines ,Vagina ,Young Adult ,cytology ,dapivirine ,preexposure prophylaxis ,vaginal ring ,MTN-020/ASPIRE and MTN-003/VOICE Study Teams ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectiveWe aimed to determine if the dapivirine vaginal ring and the ring device alone (flexible silicone matrix polymer) was associated with the development of cervical cytology abnormalities.DesignSecondary analysis comparing cervical cytology results between two randomized controlled microbicide trials (MTN-020/ASPIRE and MTN-003/VOICE).MethodsData from ASPIRE, a phase III, placebo-controlled trial of the dapivirine vaginal ring, were used in this analysis. Cervical cytology smears were evaluated at baseline and at the final visit with product use. We compared cytology results between women randomized to dapivirine versus placebo vaginal ring. We further assessed for the effect of the vaginal ring device on cervical cytology by comparing results with data from the oral placebo arm of VOICE, a prior HIV-1 prevention trial conducted in a similar population.ResultsCervical cytology results for 2394 women from ASPIRE (1197 per study arm) were used in this analysis; median time between baseline and final visit with product use was 22.1 months. Cytology smear findings were comparable between dapivirine and placebo vaginal ring arms: at final visit, normal: 90.6 versus 91.5%, ASC-US//LSIL: 7.8 versus 7.4%, ASC-H/HSIL/AGC/AGC-favor neoplastic: 1.7 versus 1.1%, P = 0.44. Cytology data from VOICE had findings (normal: 87.8%, ASC-US/LSIL: 9.8%, ASC-H/HSIL/AGC/AGC-favor neoplastic: 2.4%) comparable with that of both dapivirine (P = 0.93) and placebo vaginal ring arms (P = 0.24).ConclusionThese findings indicate that neither use of the dapivirine vaginal ring nor the vaginal ring device alone, over a period of 2 years, is associated with development of cervical cytology abnormalities that could lead to precancerous or cancerous lesions.
- Published
- 2020
29. Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings.
- Author
-
Gandhi, Monica, Wang, Guohong, King, Roger, Rodrigues, Warren C, Vincent, Michael, Glidden, David V, Cressey, Tim R, Bacchetti, Peter, Spinelli, Matthew A, Okochi, Hideaki, Siriprakaisil, Oraphan, Klinbuayaem, Virat, Mugo, Nelly R, Ngure, Kenneth, Drain, Paul K, and Baeten, Jared M
- Subjects
Biomedical and Clinical Sciences ,Sexually Transmitted Infections ,HIV/AIDS ,Bioengineering ,Clinical Research ,Clinical Trials and Supportive Activities ,Prevention ,Infectious Diseases ,Infection ,Good Health and Well Being ,Anti-HIV Agents ,Chromatography ,Liquid ,Gold ,HIV Infections ,Humans ,Medication Adherence ,Metal Nanoparticles ,Point-of-Care Testing ,Pre-Exposure Prophylaxis ,Tandem Mass Spectrometry ,Tenofovir ,adherence ,antiretroviral treatment ,lateral flow assay ,point-of-care ,preexposure prophylaxis ,tenofovir ,urine ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectiveHIV prevention and treatment studies demonstrate that pharmacologic adherence metrics are more accurate than self-report. Currently available metrics use liquid-chromatography/tandem-mass-spectrometry (LC-MS/MS), which is expensive and laboratory-based. We developed a specific and sensitive antibody against tenofovir, the backbone of treatment and prevention, but conversion to a lateral flow assay (LFA) - analogous to a urine pregnancy test - is required for point-of-care testing. We describe the development of the first LFA to measure antiretroviral adherence in real-time.MethodsPrevious work in a directly observed therapy study of providing tenofovir disoproxil fumarate (TDF) to HIV-noninfected volunteers at various simulated adherence patterns defined the appropriate cut-off for the LFA (1500 ng tenofovir/ml urine). We developed the LFA using a sample pad for urine; a conjugate pad coated with TFV-specific antibodies conjugated to colloidal gold nanoparticles; a nitrocellulose membrane striped with tenofovir-antigen (test line) and a control line; with an absorbent pad to draw urine across the reaction membrane.ResultsWe tested 300 urine samples collected from the directly observed therapy study by this LFA and the gold-standard method of LC-MS/MS. The LFA demonstrated 97% specificity (95% CI 93-99%) and 99% sensitivity (94-100%) compared with LC-MS/MS. The LFA accurately classified 98% of patients who took a dose within 24 h as adherent.ConclusionWe describe the development and validation of the first point-of-care assay to measure short-term adherence to HIV prevention and treatment in routine settings. The assay is low-cost, easy-to-perform and measures the breakdown product (tenofovir) of both TDF and tenofovir alafenamide (TAF). This assay has the potential to improve HIV and PrEP outcomes worldwide by triggering differentiated service delivery with further study merited.
- Published
- 2020
30. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?
- Author
-
Joseph Davey, Dvora L, Pintye, Jillian, Baeten, Jared M, Aldrovandi, Grace, Baggaley, Rachel, Bekker, Linda-Gail, Celum, Connie, Chi, Benjamin H, Coates, Thomas J, Haberer, Jessica E, Heffron, Renee, Kinuthia, John, Matthews, Lynn T, McIntyre, James, Moodley, Dhayendre, Mofenson, Lynne M, Mugo, Nelly, Myer, Landon, Mujugira, Andrew, Shoptaw, Steven, Stranix-Chibanda, Lynda, John-Stewart, Grace, and PrEP in Pregnancy Working Group
- Subjects
PrEP in Pregnancy Working Group ,Humans ,HIV-1 ,Pregnancy Complications ,Infectious ,HIV Infections ,Anti-HIV Agents ,Postnatal Care ,Breast Feeding ,Pregnancy ,Adult ,Female ,Young Adult ,Pre-Exposure Prophylaxis ,Tenofovir ,HIV ,PMTCT ,PrEP ,breastfeeding ,preexposure prophylaxis ,pregnancy ,prevention of mother to child transmission ,Pregnancy Complications ,Infectious ,Clinical Sciences ,Public Health and Health Services ,Other Medical and Health Sciences - Abstract
IntroductionHIV incidence is high during pregnancy and breastfeeding with HIV acquisition risk more than doubling during pregnancy and the postpartum period compared to when women are not pregnant. The World Health Organization recommends offering pre-exposure prophylaxis (PrEP) to pregnant and postpartum women at substantial risk of HIV infection. However, maternal PrEP national guidelines differ and most countries with high maternal HIV incidence are not offering PrEP. We conducted a systematic review of recent research on PrEP safety in pregnancy to inform national policy and rollout.MethodsWe used a standard Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) approach to conduct a systematic review by searching for completed, ongoing, or planned PrEP in pregnancy projects or studies from clinicaltrials.gov, PubMed and NIH RePORTER from 2014 to March 2019. We performed a systematic review of studies that assess tenofovir disoproxil fumarate (TDF)-based oral PrEP safety in pregnant and breastfeeding HIV-uninfected women.Results and discussionWe identified 14 completed (n = 5) and ongoing/planned (n = 9) studies that evaluate maternal and/or infant outcomes following PrEP exposure during pregnancy or breastfeeding. None of the completed studies found differences in pregnancy or perinatal outcomes associated with PrEP exposure. Nine ongoing studies, to be completed by 2022, will provide data on >6200 additional PrEP-exposed pregnancies and assess perinatal, infant growth and bone health outcomes, expanding by sixfold the data on PrEP safety in pregnancy. Research gaps include limited data on (1) accurately measured PrEP exposure within maternal and infant populations including drug levels needed for maternal protection; (2) uncommon perinatal outcomes (e.g. congenital anomalies); (3) infant outcomes such as bone growth beyond one year following PrEP exposure; (4) outcomes in HIV-uninfected women who use PrEP during pregnancy and/or lactation.ConclusionsExpanding delivery of PrEP is an essential strategy to reduce HIV incidence in pregnancy and breastfeeding women. Early safety studies of PrEP among pregnant women without HIV infection are reassuring and ongoing/planned studies will contribute extensive new data to bolster the safety profile of PrEP use in pregnancy. However, addressing research gaps is essential to expanding PrEP delivery for women in the context of pregnancy.
- Published
- 2020
31. Emerging evidence from a systematic review of safety of pre‐exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?
- Author
-
Davey, Dvora L Joseph, Pintye, Jillian, Baeten, Jared M, Aldrovandi, Grace, Baggaley, Rachel, Bekker, Linda‐Gail, Celum, Connie, H, Benjamin, Coates, Thomas J, Haberer, Jessica E, Heffron, Renee, Kinuthia, John, Matthews, Lynn T, McIntyre, James, Moodley, Dhayendre, Mofenson, Lynne M, Mugo, Nelly, Myer, Landon, Mujugira, Andrew, Shoptaw, Steven, Stranix‐Chibanda, Lynda, John‐Stewart, Grace, and Group, for the PrEP in Pregnancy Working
- Subjects
Biomedical and Clinical Sciences ,Midwifery ,Public Health ,Health Sciences ,Reproductive Medicine ,Breastfeeding ,Lactation and Breast Milk ,HIV/AIDS ,Sexually Transmitted Infections ,Prevention ,Pregnancy ,Maternal Health ,Infectious Diseases ,Maternal Morbidity and Mortality ,Pediatric ,Women's Health ,Perinatal Period - Conditions Originating in Perinatal Period ,Reproductive health and childbirth ,Infection ,Good Health and Well Being ,Adult ,Anti-HIV Agents ,Breast Feeding ,Female ,HIV Infections ,HIV-1 ,Humans ,Postnatal Care ,Pre-Exposure Prophylaxis ,Pregnancy Complications ,Infectious ,Tenofovir ,Young Adult ,preexposure prophylaxis ,PrEP ,pregnancy ,breastfeeding ,PMTCT ,prevention of mother to child transmission ,HIV ,PrEP in Pregnancy Working Group ,Clinical Sciences ,Public Health and Health Services ,Other Medical and Health Sciences ,Clinical sciences ,Epidemiology ,Public health - Abstract
IntroductionHIV incidence is high during pregnancy and breastfeeding with HIV acquisition risk more than doubling during pregnancy and the postpartum period compared to when women are not pregnant. The World Health Organization recommends offering pre-exposure prophylaxis (PrEP) to pregnant and postpartum women at substantial risk of HIV infection. However, maternal PrEP national guidelines differ and most countries with high maternal HIV incidence are not offering PrEP. We conducted a systematic review of recent research on PrEP safety in pregnancy to inform national policy and rollout.MethodsWe used a standard Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) approach to conduct a systematic review by searching for completed, ongoing, or planned PrEP in pregnancy projects or studies from clinicaltrials.gov, PubMed and NIH RePORTER from 2014 to March 2019. We performed a systematic review of studies that assess tenofovir disoproxil fumarate (TDF)-based oral PrEP safety in pregnant and breastfeeding HIV-uninfected women.Results and discussionWe identified 14 completed (n = 5) and ongoing/planned (n = 9) studies that evaluate maternal and/or infant outcomes following PrEP exposure during pregnancy or breastfeeding. None of the completed studies found differences in pregnancy or perinatal outcomes associated with PrEP exposure. Nine ongoing studies, to be completed by 2022, will provide data on >6200 additional PrEP-exposed pregnancies and assess perinatal, infant growth and bone health outcomes, expanding by sixfold the data on PrEP safety in pregnancy. Research gaps include limited data on (1) accurately measured PrEP exposure within maternal and infant populations including drug levels needed for maternal protection; (2) uncommon perinatal outcomes (e.g. congenital anomalies); (3) infant outcomes such as bone growth beyond one year following PrEP exposure; (4) outcomes in HIV-uninfected women who use PrEP during pregnancy and/or lactation.ConclusionsExpanding delivery of PrEP is an essential strategy to reduce HIV incidence in pregnancy and breastfeeding women. Early safety studies of PrEP among pregnant women without HIV infection are reassuring and ongoing/planned studies will contribute extensive new data to bolster the safety profile of PrEP use in pregnancy. However, addressing research gaps is essential to expanding PrEP delivery for women in the context of pregnancy.
- Published
- 2020
32. Social harms in female-initiated HIV prevention method research: state of the evidence.
- Author
-
Montgomery, Elizabeth T, Roberts, Sarah T, Nel, Annalene, Malherbe, Mariette, Torjesen, Kristine, Bunge, Katherine, Singh, Devika, Baeten, Jared M, Marrazzo, Jeanne, Chirenje, Z Mike, Kabwigu, Samuel, Beigi, Richard, Riddler, Sharon A, Gaffour, Zakir, Reddy, Krishnaveni, Mansoor, Leila E, Nair, Gonasagrie, Woeber, Kusbashni, Moodley, Jayajothi, Jeenarain, Nitesha, Siva, Samantha, Naidoo, Logashvari, Govender, Vaneshree, and Palanee-Phillips, Thesla
- Subjects
Biomedical and Clinical Sciences ,Health Services and Systems ,Public Health ,Health Sciences ,Clinical Sciences ,Topical Microbicides ,Behavioral and Social Science ,HIV/AIDS ,Prevention ,Clinical Research ,Infectious Diseases ,Mental Health ,Patient Safety ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Africa South of the Sahara ,Anti-HIV Agents ,Double-Blind Method ,Ethics ,Research ,Female ,HIV Infections ,Humans ,Intimate Partner Violence ,Male ,Patient Participation ,Prospective Studies ,Safety ,Vaginal Creams ,Foams ,and Jellies ,Africa ,HIV ,microbicide ,social harms ,women ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectivesAssessment of safety is an integral part of real-time monitoring in clinical trials. In HIV prevention research, safety of investigational products and trial participation has been expanded to include monitoring for 'social harms', generally defined as negative consequences of trial participation that may manifest in social, psychological, or physical ways. Further research on social harms within HIV prevention research is needed to understand the potential safety risks for women and advance the implementation of prevention methods in real-world contexts.MethodsSecondary analysis of quantitative data from three randomized, double-blind, placebo-controlled trials of microbicide candidates in sub-Saharan Africa was conducted. Additionally, we assessed data from two prospective cohort studies that included participants who became HIV-positive or pregnant during parent trials.ResultsSocial harms reporting was low across the largest and most recent microbicide studies. Social harm incidence per 100 person-years ranged from 1.10 (95% CI 0.78-1.52) to 3.25 (95% CI 2.83-3.74) in the phased trials. Reporting differed by dosing mechanism (e.g. vaginal gel, oral tablet, ring) and study, most likely as a function of measurement differences. Social harms were most frequently associated with male partners, rather than, for example, experiences of stigma in the community.ConclusionMeasurement and screening for social harms is an important component of conducting ethical research of novel HIV prevention methods. To date, social harm incidence reported in microbicide trials has been relatively low (
- Published
- 2019
33. A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.
- Author
-
Patel, Rena C, Stalter, Randy M, Thomas, Katherine K, Tamraz, Bani, Blue, Steven W, Erikson, David W, Kim, Christina J, Kelly, Edward J, Nanda, Kavita, Kourtis, Athena P, Lingappa, Jairam R, Mugo, Nelly, Baeten, Jared M, and Scarsi, Kimberly K
- Subjects
Genetics ,Clinical Research ,Contraception/Reproduction ,Patient Safety ,HIV/AIDS ,Infectious Diseases ,Good Health and Well Being ,Adult ,Alkynes ,Anti-HIV Agents ,Benzoxazines ,Contraceptive Agents ,Female ,Cyclopropanes ,Desogestrel ,Drug Antagonism ,Female ,HIV Infections ,Humans ,Kenya ,Levonorgestrel ,Linear Models ,Nevirapine ,Pharmacogenomic Testing ,Uganda ,antiretroviral therapy ,efavirenz ,etonogestrel ,hormonal contraception ,implants ,levonorgestrel ,pharmacogenetic ,pharmacokinetic ,Partners PrEP Study Team ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology - Abstract
ObjectivesTo evaluate pharmacokinetics and pharmacogenetics of contraceptive implant progestin concentrations in HIV-positive women initiating efavirenz (EFV)-containing or nevirapine (NVP)-containing antiretroviral therapy (ART).DesignWe analyzed stored samples from women self-reporting implant use in the Partners PrEP Study.MethodsPlasma samples collected every 6 months were analyzed for levonorgestrel and etonogestrel concentrations. Progestin concentrations from samples collected after ART initiation were compared with pre-ART concentrations for intraindividual comparisons. We used adjusted linear mixed models to compare hormone concentrations between individuals on EFV and NVP to a no ART group. We then evaluated whether possessing certain alleles with known or possible influences on EFV, NVP, or progestin metabolism were associated with changes in progestin concentrations or modified the association between ART use and progestin concentrations.ResultsOur analysis included 11 women who initiated EFV, 13 who initiated NVP, and 36 who remained ART-naive. In the EFV group, the adjusted geometric mean ratio (aGMR) of levonorgestrel was 0.39 [90% confidence intervals (0.31, 0.49); P
- Published
- 2019
34. PrEP initiation, persistence, and adherence during pregnancy through the postpartum period: a prospective analysis in Kenya
- Author
-
Pintye, Jillian, Kinuthia, John, Abuna, Felix, Anderson, Peter L., Dettinger, Julia C., Gomez, Laurén, Haberer, Jessica E., Marwa, Mary, Mwongeli, Nancy, Omondi, Pascal., Ochieng, Ben, Stern, Joshua, Watoyi, Salphine, Baeten, Jared M., and John-Stewart, Grace
- Published
- 2023
- Full Text
- View/download PDF
35. HIV pre-exposure prophylaxis initiation, persistence, and adherence during pregnancy through the postpartum period
- Author
-
Pintye, Jillian, Kinuthia, John, Abuna, Felix, Anderson, Peter L., Dettinger, Julia C., Gomez, Laurén, Haberer, Jessica E., Marwa, Mary M., Ngumbau, Nancy, Omondi, Pascal, Odhiambo, Ben, Stern, Joshua, Watoyi, Salphine, Baeten, Jared M., and John-Stewart, Grace
- Published
- 2023
- Full Text
- View/download PDF
36. A decision support tool has similar high PrEP uptake and increases early PrEP persistence in adolescent girls and young women in South Africa: results from a randomized controlled trial
- Author
-
Celum, Connie, Seidman, Dominika, Travill, Danielle, Dehlendorf, Christine, Gumede, Sanele, Zewdie, Kidist, Wilson, Whitney, Morton, Jennifer F., Baeten, Jared M., Donnell, Deborah, and Delany‐Moretlwe, Sinead
- Subjects
Health behavior -- Evaluation ,HIV infection -- Prevention ,Teenage girls -- Drug therapy ,Health - Abstract
: Introduction: African adolescent girls and young women (AGYW) have high rates of HIV acquisition and are a priority population for HIV pre‐exposure prophylaxis (PrEP). PrEP implementation has been limited by AGYW's low perceived HIV risk and provider demands. A decision support tool (DST) with information about PrEP could improve clients’ risk perception, knowledge about PrEP, informed decision‐making and motivation to use PrEP based on their risk, facilitating PrEP delivery in primary healthcare (PHC) clinics. Methods: We designed MyPrEP, a client‐facing DST about PrEP and HIV prevention, with youth‐friendly information and images. The impact of the MyPrEP tool was assessed among HIV‐negative women aged 18–25 years presenting to a PHC clinic in Johannesburg, South Africa from March 2019 to 2020. AGYW were randomized by day to the DST or a general health website as the control condition. A clinician blinded to DST versus control allocation provided standard of care counselling about PrEP, offered PrEP, administered a questionnaire and conducted sexually transmitted infection testing. The primary outcome was PrEP initiation and the secondary outcome was PrEP persistence at 1 month, determined by pharmacy dispensation records. Results: Of 386 AGYW screened, 353 were randomized (DST n = 172, control n = 181) with a median age of 21 years (interquartile range [IQR] 20, 23) and 56% (199/353) attending the clinic for HIV testing, 46% (164/353) using contraception, 15% (53/353) using condoms consistently and 37% (108/353) with a curable sexually transmitted infection. PrEP was initiated by 97% in the DST group and 94% in the control group (OR 1.79; 95% confidence interval, CI = 0.79–1.53), of whom two‐thirds planned to continue PrEP until they decided if they liked PrEP. At 1 month, PrEP persistence was 19% in the DST and 10% in the control group (OR 1.97, 95% CI 1.08–3.69). Ninety‐nine percent randomized to the DST reported satisfaction with MyPrEP. Conclusions: Among AGYW attending a South African PHC clinic, PrEP uptake was >90% with two‐fold higher PrEP persistence at 1 month in those randomized to use the MyPrEP DST. Given the need for strategies to support PrEP implementation and improve low PrEP persistence among African AGYW, a PrEP DST warrants further evaluation., INTRODUCTION Adolescent girls and young women (AGYW) in Africa account for 25% of new HIV infections globally [1]. While pre‐exposure prophylaxis (PrEP) is highly effective when taken consistently [2], AGYW [...]
- Published
- 2023
- Full Text
- View/download PDF
37. Patterns of PrEP continuation and coverage in the first year of use: a latent class analysis of a programmatic PrEP trial in Kenya
- Author
-
Mugwanya, Kenneth K., Palayew, Adam, Schaafsma, Torin, Irungu, Elizabeth M., Bukusi, Elizabeth, Mugo, Nelly, Morton, Jennifer, Odoyo, Josephine, Ngure, Kenneth, and Baeten, Jared M.
- Subjects
Patient compliance -- Evaluation ,Public health administration -- Evaluation ,HIV infection -- Prevention ,Health - Abstract
: Introduction: Effective PrEP use is critical for impact, but data are limited on common patterns of continuation and coverage among persons using PrEP in real‐world settings. Methods: Data are from the Partners Scale‐Up Project, a programmatic stepped‐wedge cluster‐randomized trial to integrate PrEP delivery in 25 Kenyan public health facilities conducted between February 2017 and December 2021. We evaluated PrEP continuation using visit attendance and pharmacy refill records, and computed medication possession ratio to define coverage during the first year of use. Latent class mixture models were used to identify and characterize membership to different PrEP continuation patterns. Multinomial logistic regression was used to examine the association between group trajectories and demographic and behaviour characteristics. Results: Overall, 4898 persons initiated PrEP, 54% (2640) were female, mean age was 33 years (standard deviation 11) and 84% (4092) had partners living with HIV. PrEP continuation was 57%, 44%, and 34% at 1, 3, and 6 months, respectively. Four unique trajectories of PrEP coverage were identified: (1) one‐fourth (1154) exhibited consistent high coverage throughout the year with 93%, 94%, 96%, and 67% continuing PrEP at months 1, 3, 6, and 12, respectively; (2) 13% (682) showed high coverage trajectory throughout 6 months but coverage rapidly declined thereafter (94%, 93%, 63%, and 10% continued at months 1, 3, 6, and 12, respectively); (3) 18.9% (918) exhibited moderate coverage trajectory with 91% of clients refilling PrEP at month 1 but nearly all dropped‐off thereafter (37%, 5%, and 4% continued at months 3, 6, and 12, respectively); and (4) 43.8% (2144) exhibited immediate discontinuation trajectory, in which nearly all did not have any subsequent PrEP refill. Overall, being female, older age, having partners living with HIV or of unknown HIV status were statistically associated with better PrEP continuation trajectories compared to the immediate discontinuation trajectory (p Conclusions: In this analysis of a real‐world PrEP implementation programme in Kenya, we found four distinct patterns of PrEP continuation, with one‐third of users exhibiting consistent high continuation throughout 12 months and two‐fifths with immediate discontinuation patterns. These data may help guide tailored interventions to support PrEP continuation in this setting., INTRODUCTION Oral pre‐exposure prophylaxis is a highly effective HIV prevention strategy for men and women when taken with its effectiveness highly dependent on adherence [1–3]. Indeed, across first‐generation clinical PrEP [...]
- Published
- 2023
- Full Text
- View/download PDF
38. PrEP uptake and HIV viral suppression when PrEP is integrated into Ugandan ART clinics for HIV-negative members of HIV-serodifferent couples: A stepped wedge cluster randomized trial
- Author
-
Heffron, Renee, (protocol chair), Baeten, Jared M., Simoni, Jane, Donnell, Deborah, Barnabas, Ruanne, Thomas, Katherine K., Thomas, Dorothy, Feutz, Erika, Grabow, Cole, Meisner, Allison, Ciccarelli, Kristin, Scoville, Caitlin, Ortblad, Katrina, Mujugira, Andrew, Muwonge, Timothy R., Kibuuka, Joseph, Nakabugo, Lylianne, Nambi, Florence, Nakitende, Mai, Izizinga, Diego, Kasita, Vicent, Kamusiime, Brenda, Nalumansi, Alisaati, Twesige, Collins, Kakoola, Grace, Brown, Charles, Namanda, Sylvia, Kadama, Herbert, Ware, Norma C., Wyatt, Monique A., Pisarski, Emily, Katz, Ingrid T., Heffron, Renee, and Simoni, Jane M.
- Published
- 2022
- Full Text
- View/download PDF
39. Predominance of high-level tetracycline-resistant Neisseria gonorrhoeae in Kenya: Implications for global implementation of doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections
- Author
-
Soge, Olusegun O., Issema, Rodal, Bukusi, Elizabeth, Baeten, Jared M., Mujugira, Andrew, Celum, Connie, McClelland, R. Scott, and Stewart, Jenell
- Published
- 2023
- Full Text
- View/download PDF
40. HIV risk associated with serum medroxyprogesterone acetate (MPA) levels among women in East and southern Africa
- Author
-
Heffron, Renee, Stalter, Randy, Pyra, Maria, Nanda, Kavita, Erikson, David W, Hladik, Florian, Blue, Steven W, Davis, Nicole L, Mugo, Nelly, Kourtis, Athena P, Lingappa, Jairam R, and Baeten, Jared M
- Subjects
HIV/AIDS ,Prevention ,Clinical Research ,Infectious Diseases ,Infection ,Good Health and Well Being ,Adult ,Africa ,Eastern ,Africa ,Southern ,Case-Control Studies ,Contraceptive Agents ,Hormonal ,Diagnostic Tests ,Routine ,Female ,HIV Infections ,Humans ,Longitudinal Studies ,Male ,Medroxyprogesterone Acetate ,Risk Assessment ,Serum ,Africa ,depot medroxyprogesterone acetate ,HIV ,hormonal contraception ,women ,Partners PrEP Study and Partners in Prevention HSV/HIV Transmission Study Teams ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology - Abstract
BackgroundSome observational studies have found increased HIV risk associated with self-reported use of injectable depot medroxyprogesterone acetate. Testing blood samples for medroxyprogesterone acetate (MPA), the progestin in depot medroxyprogesterone acetate, permits validation of self-reported data, and exploration of whether potential HIV risk is correlated with MPA levels, which are highest soon after injection.MethodsWe conducted a case-control study testing archived serum from women who participated in three longitudinal studies of HIV prevention in East and southern Africa. Case samples, from women who acquired HIV, were from visits that occurred at or immediately prior to the first evidence of HIV infection. Secondary analyses restricted to case samples collected within 15 and 30 days of the estimated date of HIV infection. Matched control samples were from women who remained HIV uninfected. We used multivariable conditional logistic regression to compare exogenous hormone levels, quantified through mass spectrometry, among cases and controls.ResultsWhen restricted to cases with samples collected within 15 days or less of estimated date of HIV infection, MPA detection was more frequent among women who acquired HIV (adjusted odds ratio = 2.75, 95% confidence interval 1.22-6.19). In this subset, the increase in HIV risk was only among samples with MPA detected at a low level of 0.02-0.50 ng/ml: 36.7% of cases and 9.4% of controls, adjusted odds ratio = 6.03, 95% confidence interval 2.50-14.54.ConclusionDetection of MPA at low levels close to the estimated time of HIV acquisition was significantly more frequent among women who acquired HIV. Studies are needed that explore biological mechanisms elicited by any MPA level and HIV risk.
- Published
- 2019
41. A clinic-based tablet application to support safer conception among HIV serodiscordant couples in Kenya: feasibility and acceptability study
- Author
-
Velloza, Jennifer, Ngure, Kenneth, Kiptinness, Catherine, Quame-Amaglo, Justice, Thuo, Nicholas, Dew, Kristin, Kimani, Mary, Gakuo, Stephen, Unger, Jennifer A, Kolko, Beth, Baeten, Jared M, Celum, Connie, Mugo, Nelly, and Heffron, Renee
- Subjects
Public Health ,Health Sciences ,Contraception/Reproduction ,Clinical Research ,Infectious Diseases ,Prevention ,HIV/AIDS ,Behavioral and Social Science ,Infection ,Reproductive health and childbirth ,Good Health and Well Being ,Africa ,HIV prevention ,mHealth ,safer conception ,tablet application ,Health services and systems ,Applied computing ,Information systems - Abstract
BackgroundHIV serodiscordant couples are at heightened risk of HIV transmission when attempting to conceive, yet reproductive goals can outweigh concerns about HIV exposure. Safer conception strategies support fertility desires while minimizing HIV transmission risk and novel mHealth tools can optimize their use. The objective of this analysis is to examine the feasibility and usability of short message service (SMS) messages and a mobile application to support safer conception for HIV serodiscordant couples.MethodsWe enrolled 74 heterosexual HIV serodiscordant couples with immediate pregnancy desires into a pilot safer conception intervention study in Thika, Kenya. Prior to pregnancy, women received daily 6-item SMS surveys to capture fertility indicators (e.g., menses, basal body temperature) and sexual behavior. The intervention also provided daily oral pre-exposure prophylaxis (PrEP) for the HIV-negative partner and in-depth counseling to accompany publicly-provided antiretroviral therapy (ART) for the HIV-infected partner. Couples attended monthly visits until pregnancy occurred. We measured PrEP use with medication event monitoring system (MEMS) caps and ART use via quarterly viral load quantification. We imported SMS, MEMS, and viral load data into an Android tablet application designed specifically for this setting for couples to view during clinic visits and included predictions of peak fertility days using SMS data. We used descriptive statistics to summarize SMS response data and developed a Google Analytics platform to monitor tablet application usage during follow-up. We also conducted semi-structured interviews with a purposive sample of 5 healthcare providers and 19 couples. Qualitative data were analyzed using a modified constant comparative approach to identify themes related to mHealth intervention feasibility and acceptability.ResultsIn our sample, 34 (45.9%) couples had an HIV-infected female partner. The median age of the female partner was 30 years [interquartile range (IQR), 27-35 years], education was 10 years (IQR, 8-12 years), and partnership duration was 3 years (IQR, 2-7 years). Couples were followed for a median of 218 days (IQR, 116-348 days) prior to pregnancy. Participants completed 13,181 of 16,905 (78.0%) SMS surveys surveys sent with a median of 167 completed surveys (IQR, 74-299) per participant. Most participants completed at least 75% of the total SMS messages received (N=58; 77.3%). The tablet application was opened by counselors 1,806 times during the study period (March 2016 through April 2018). In qualitative interviews, the SMS messages were reportedly easy to respond to and "part of the daily routine". Few participants had concerns about message confidentiality. mHealth tools were also found to be acceptable for tracking fertility indicators and enhancing provider-patient communication.ConclusionsmHealth strategies are feasible to use and acceptable to support the delivery of safer conception intervention services among HIV serodiscordant couples in Kenya.
- Published
- 2019
42. Implementation strategies for integrating pre-exposure prophylaxis for HIV prevention and family planning services for adolescent girls and young women in Kenya: a qualitative study
- Author
-
Roche, Stephanie D., Barnabee, Gena, Omollo, Victor, Mogaka, Felix, Odoyo, Josephine, Bukusi, Elizabeth A., Morton, Jennifer F., Johnson, Rachel, Celum, Connie, Baeten, Jared M., and O’Malley, Gabrielle
- Published
- 2022
- Full Text
- View/download PDF
43. Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis: study protocol for an open-label randomized trial
- Author
-
Stewart, Jenell, Bukusi, Elizabeth, Sesay, Fredericka A., Oware, Kevin, Donnell, Deborah, Soge, Olusegun O., Celum, Connie, Odoyo, Josephine, Kwena, Zachary A., Scoville, Caitlin W., Violette, Lauren R., Morrison, Susan, Simoni, Jane, McClelland, R. Scott, Barnabas, Ruanne, Gandhi, Monica, and Baeten, Jared M.
- Published
- 2022
- Full Text
- View/download PDF
44. Women's preferences for HIV prevention service delivery in pharmacies during pregnancy in Western Kenya: a discrete choice experiment.
- Author
-
Mugambi, Melissa Latigo, Odhiambo, Ben O., Dollah, Annabell, Marwa, Mary M., Nyakina, Judith, Kinuthia, John, Baeten, Jared M., Weiner, Bryan J., John‐Stewart, Grace, Barnabas, Ruanne Vanessa, and Hauber, Brett
- Subjects
HIV prevention ,PRE-exposure prophylaxis ,SEXUALLY transmitted diseases ,DIAGNOSIS of HIV infections ,TRAVEL time (Traffic engineering) ,CHILDBEARING age - Abstract
Introduction: Pharmacy‐delivered HIV prevention services might create more options for pregnant women to use HIV prevention tools earlier and more consistently during pregnancy. We quantified preferences for attributes of potential HIV prevention services among women of childbearing age in Western Kenya. Methods: From June to November 2023, we administered a face‐to‐face discrete choice experiment survey to women aged 15–44 in Kenya's Homa Bay, Kisumu and Siaya counties. The survey evaluated preferences for HIV prevention services, described by seven attributes: service location, travel time, type of HIV test, sexually transmitted infection (STI) testing, partner HIV testing, pre‐exposure prophylaxis (PrEP) and service fee. Participants answered a series of 12‐choice questions. Each question asked them to select one of two service options or no services—an opt‐out option. We used hierarchical Bayesian modelling levels to estimate each attribute level's coefficient and understand how attributes influenced service choice. Results: Overall, 599 participants completed the survey, among whom the median age was 23 years (IQR: 18–27); 33% were married, 20% had a job and worked regularly, and 52% had been pregnant before. Participants, on average, strongly preferred having any HIV prevention service option over none (opt‐out preference weight: −5.84 [95% CI: −5.97, −5.72]). The most important attributes were the availability of PrEP (relative importance 27.04% [95% CI: 25.98%, 28.11%]), followed by STI testing (relative importance 20.26% [95% CI: 19.52%, 21.01%]) and partner HIV testing (relative importance: 16.35% [95% CI: 15.79%, 16.90%]). While, on average, participants preferred obtaining services at the clinic more than pharmacies, women prioritized the availability of PrEP, STI testing and partner HIV testing more than the location or cost. Conclusions: These findings suggest the importance of providing comprehensive HIV prevention services and ensuring PrEP, STI testing and partner HIV testing are available. If pharmacies can offer these services, women are likely to access those services at pharmacies even if they prefer clinics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Stand‐alone model for delivery of oral HIV pre‐exposure prophylaxis in Kenya: a single‐arm, prospective pilot evaluation
- Author
-
Ortblad, Katrina F., Mogere, Peter, Omollo, Victor, Kuo, Alexandra P., Asewe, Magdaline, Gakuo, Stephen, Roche, Stephanie, Mugambi, Mary, Mugambi, Melissa Latigo, Stergachis, Andy, Odoyo, Josephine, Bukusi, Elizabeth A., Ngure, Kenneth, and Baeten, Jared M.
- Subjects
Drugstores -- Services ,HIV infection -- Prevention ,Company distribution practices ,Health - Abstract
: Introduction: The delivery of daily, oral HIV pre‐exposure prophylaxis (PrEP) at private pharmacies may overcome barriers to PrEP delivery at public healthcare facilities, including HIV‐associated stigma, long wait times and overcrowding. Methods: At five private, community‐based pharmacies in Kenya, a care pathway for PrEP delivery (ClinicalTrials.gov: NCT04558554) was piloted—the first of its kind in Africa. Pharmacy providers screened clients interested in PrEP for HIV risk, then used a prescribing checklist to identify clients without medical conditions that might contraindicate PrEP safety, counsel them on PrEP use and safety, conduct provider‐assisted HIV self‐testing and dispense PrEP. For complex clinical cases, a remote clinician was available for consultation. Clients who did not meet the checklist criteria were referred to public facilities for free services delivered by clinicians. Pharmacy providers dispensed a 1‐month PrEP supply at initiation and a 3‐month supply thereafter at a client fee of 300 KES (∼$3 USD) per visit. Results: From November 2020 to October 2021, pharmacy providers screened 575 clients, identified 476 who met the prescribing checklist criteria and initiated 287 (60%) on PrEP. Among pharmacy PrEP clients, the median age was 26 years (IQR 22–33) and 57% (163/287) were male. The prevalence of behaviours associated with HIV risk among clients was high; 84% (240/287) reported sexual partners with unknown HIV status and 53% (151/287) reported multiple sexual partners (past 6 months). PrEP continuation among clients was 53% (153/287) at 1 month, 36% (103/287) at 4 months and 21% (51/242) at 7 months. During the pilot observation period, 21% (61/287) of clients stopped and restarted PrEP and overall pill coverage was 40% (IQR 10%–70%). Nearly, all pharmacy PrEP clients (≥96%) agreed or strongly agreed with statements regarding the acceptability and appropriateness of pharmacy‐delivered PrEP services. Conclusions: Findings from this pilot suggest that populations at HIV risk frequently visit private pharmacies and PrEP initiation and continuation at pharmacies is similar to or exceeds that at public healthcare facilities. Private pharmacy‐based PrEP delivery, conducted entirely by private‐sector pharmacy staff, is a promising new delivery model that has the potential to expand PrEP reach in Kenya and similar settings., INTRODUCTION Despite the availability of free HIV testing, treatment and daily, oral pre‐exposure prophylaxis (PrEP) at public healthcare facilities in many sub‐Saharan African countries [1, 2], HIV incidence persists above [...]
- Published
- 2023
- Full Text
- View/download PDF
46. Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
- Author
-
Donnell, Deborah, Gao, Fei, Hughes, James P., Hanscom, Brett, Corey, Lawrence, Cohen, Myron S., Edupuganti, Srilatha, Mgodi, Nyaradzo, Rees, Helen, Baeten, Jared M., Gray, Glenda, Bekker, Linda‐Gail, Hosseinipour, Mina, and Delany‐Moretlwe, Sinead
- Subjects
Women -- Health aspects ,HIV infection -- Prevention ,Company business management ,Health - Abstract
: Introduction: Multiple antiretroviral agents have demonstrated efficacy for human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP). As a result, clinical trials of novel agents have transitioned from placebo‐ to active‐controlled designs; however, active‐controlled trials do not provide an estimate of efficacy versus no use of PrEP. Counterfactual placebo comparisons using other data sources could be employed to provide this information. Methods: We compared the active‐controlled study (HPTN 084) of injectable cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) among women from seven countries in Africa to three external, contemporaneous randomized HIV prevention trials from which we constructed counterfactual placebo estimates. We used direct standardization via analysis weights to achieve the same distribution of person‐years between the external study and HPTN 084, across strata predictive of HIV risk (country and selected risk covariates). We estimated prevention efficacy against a counterfactual placebo to provide information on the use of CAB‐LA and FTC/TDF compared to no intervention. We compared the counterfactual placebo findings for FTC/TDF to previous placebo‐controlled trials, adjusted for observed adherence to daily pills. Results: Distribution of age and baseline prevalence of gonorrhoea and chlamydia were similar among matched counterfactual placebo and observed HPTN 084 arms after standardization. Counterfactual estimates of CAB‐LA versus placebo in all three settings showed a consistent risk reduction of 93%–94%, with lower bounds of the confidence intervals above 72%. Observed adherence (quantifiable tenofovir in plasma) in HPTN 084 was 54%–56%, and estimated efficacy of daily oral FTC/TDF against a counterfactual placebo was consistent with a predicted risk reduction of 39%–40% for this level of daily pill use. Conclusions: Counterfactual placebo rates of HIV acquisition derived from external trial data in similar locations and time can be used to support estimates of placebo‐based efficacy of a novel HIV prevention agent. External trial data must be standardized to be representative of the clinical trial cohort testing the novel HIV prevention agent, accounting for confounders., INTRODUCTION The daily oral pill pre‐exposure prophylaxis (PrEP) regimen containing emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduces human immunodeficiency virus (HIV) by >90%, when used as prescribed [1–3]. While “biological efficacy” of [...]
- Published
- 2023
- Full Text
- View/download PDF
47. A one-stop shop model for improved efficiency of pre-exposure prophylaxis delivery in public clinics in western Kenya: a mixed methods implementation science study
- Author
-
Roche, Stephanie D., Odoyo, Josephine, Irungu, Elizabeth, Kwach, Benn, Dollah, Annabell, Nyerere, Bernard, Peacock, Sue, Morton, Jennifer F., O'Malley, Gabrielle, Bukusi, Elizabeth A., Baeten, Jared M., and Mugwanya, Kenneth K.
- Subjects
Community health services -- Quality management ,Clinics -- Quality management ,HIV infection -- Prevention ,Health - Abstract
Introduction: In public clinics in Kenya, separate, sequential delivery of the component services of pre-exposure prophylaxis (PrEP) (e.g. HIV testing, counselling, and dispensing) creates long wait times that hinder clients' ability and desire to access and continue PrEP. We conducted a mixed methods study in four public clinics in western Kenya to identify strategies for operationalizing a one-stop shop (OSS) model and evaluate whether this model could improve client wait time and care accept-ability among clients and providers without negatively impacting uptake or continuation. Methods: From January 2020 through November 2020, we collected and analysed 47 time-and-motion observations using Mann-Whitney U tests, 29 provider and client interviews, 68 technical assistance reports, and clinic flow maps from inter-vention clinics. We used controlled interrupted time series (cITS) to compare trends in PrEP initiation and on-time returns from a 12-month pre-intervention period (January-December 2019) to an 8-month post-period (January-November 2020, excluding a 3-month COVID-19 wash-out period) at intervention and controlclinics. Results: From the pre- to post-period, median client wait time at intervention clinics dropped significantly from 31 to 6 minutes (p = 0.02), while median provider contact time remained around 23 minutes (p = 0.4). Intervention clinics achieved efficiency gains by moving PrEP delivery to lower volume departments, moving steps closer together (e.g. relocating supplies; cross-training and task-shifting), and differentiating clients based on the subset of services needed. Clients and providers found the OSS model highly acceptable and additionally identified increased privacy, reduced stigma, and higher quality client-provider interactions as benefits of the model. From the pre- to post-period, average monthly initiations at intervention and control clinics increased by 6 and 2.3, respectively, and percent of expected follow-up visits occurring on time decreased by 18% and 26%, respectively; cITS analysis of PrEP initiations (n = 1227) and follow-up visits (n = 2696) revealed no significant difference between intervention and control clinics in terms of trends in PrEP initiation and on-time returns (all p>0.05). Conclusions: An OSS model significantly improved client wait time and care acceptability without negatively impacting initiations or continuations, thus highlighting opportunities to improve the efficiency of PrEP delivery efficiency and client-centredness. Keywords: HIV prevention; implementation science; Kenya; organizational efficiency; pre-exposure prophylaxis; quality improvement, 1 | INTRODUCTION In the 6 years since the World Health Organization released guidelines recommending daily oral tenofovir-based pre-exposure prophylaxis (PrEP) for populations at substantial risk of HIV infection [1], [...]
- Published
- 2021
- Full Text
- View/download PDF
48. HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial
- Author
-
Parikh, Urvi M., Penrose, Kerri J., Heaps, Amy L., Halvas, Elias K., Goetz, B.Jay, Gordon, Kelley C., Hardesty, Russell, Sethi, Rahil, Schwarzmann, William, Szydlo, Daniel W., Husnik, Marla J., Chandran, Uma, Palanee-Phillips, Thesla, Baeten, Jared M., and Mellors, John W.
- Subjects
Gene mutations -- Health aspects ,Serology ,Antiviral agents -- Testing ,Drug resistance -- Genetic aspects ,Anti-HIV agents -- Testing ,Health - Abstract
Introduction: A potential concern with the use of dapivirine (DPV) for HIV prevention is the selection of a drug-resistant virus that could spread and reduce the effectiveness of non-nucleoside reverse transcriptase (NNRTI)-based first-line antiretroviral therapy. We evaluated HIV-1 seroconversions in MTN-020/ASPIRE for selection of drug resistance and evaluated the genetic basis for observed reductions in susceptibility to DPV. Methods: MTN-020/ASPIRE was a placebo-controlled, Phase III safety and effectiveness study of DPV ring for HIV-1 prevention conducted at 15 sites in South Africa, Zimbabwe, Malawi and Uganda between 2012 and 2015. Plasma from individuals who seroconverted in ASPIRE was analysed for HIV-1 drug resistance using both population Sanger sequencing and next-generation sequencing (NGS) with unique molecular identifiers to report mutations at [greater than or equal to]1% frequency. DPV susceptibility of plasma-derived recombinant HIV-1 containing bulk-cloned full-length reverse transcriptase sequences from MTN-020/ASPIRE seroconversions was determined in TZM-blcells. Statistical significance was calculated using the Fisher's exact test. Results: Plasma from all 168 HIV seroconversions were successfully tested by Sanger sequencing; 57 of 71 DPV arm and 82 of 97 placebo (PLB) arm participants had NGS results at 1% sensitivity. Overall, 18/168 (11%) had NNRTI mutations including K101E, K103N/S, V106M, V108I, E138A/G, V179D/I/T and H221Y. Five samples from both arms had low-frequency NNRTI mutations that were not detected by Sanger sequencing. The frequency of NNRTI mutations from the DPV arm (11%) was not different from the PLB arm (10%; p = 0.80). The E138A mutation was detected in both the DPV (3 of 71 [4.2%]) and PLB arm (5 of 97 [5.2%]) and conferred modest reductions in DPV susceptibility in some reverse transcriptase backgrounds but not others. Conclusions: HIV-1 drug resistance including NNRTI resistance did not differ between the DPV and placebo arms of the MTN-020/ASPIRE study, indicating that drug resistance was not preferentially acquired or selected by the DPV ring and that the preventive benefit of DPV ring outweighs resistance risk. Keywords: dapivirine; HIV-1 drug resistance; HIV-1 prevention; next-generation sequencing; non-nucleoside reverse transcriptase inhibitors (NNRTI); pre-exposure prophylaxis (PrEP), INTRODUCTION Women in Sub-Saharan Africa have a disproportionate risk of HIV infection [1], highlighting the pressing need for safe and effective prevention strategies that allow for agency and choice. Dapivirine [...]
- Published
- 2021
- Full Text
- View/download PDF
49. Nurse-facilitated preexposure prophylaxis delivery for adolescent girls and young women seeking contraception at retail pharmacies in Kisumu, Kenya
- Author
-
Pintye, Jillian, Odoyo, Josephine, Nyerere, Bernard, Achieng, Pauline, Araka, Evelyne, Omondi, Christine, Ortblad, Katrina F., Mugambi, Melissa L., Baeten, Jared M., and Bukusi, Elizabeth A.
- Published
- 2023
- Full Text
- View/download PDF
50. Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence.
- Author
-
Gandhi, Monica, Bacchetti, Peter, Rodrigues, Warren C, Spinelli, Matthew, Koss, Catherine A, Drain, Paul K, Baeten, Jared M, Mugo, Nelly R, Ngure, Kenneth, Benet, Leslie Z, Okochi, Hideaki, Wang, Guohong, and Vincent, Michael
- Subjects
Antibody ,Antiretroviral adherence ,Antiretroviral treatment ,Immunoassay ,Point-of-care ,PrEP ,Real-time ,Tenofovir ,Test characteristics ,Urine ,Clinical Trials and Supportive Activities ,Prevention ,HIV/AIDS ,Clinical Research ,4.2 Evaluation of markers and technologies ,tenofovir ,immunoassay ,antibody ,antiretroviral treatment ,real-time ,point-of-care ,urine ,test characteristics - Abstract
BackgroundPharmacologic adherence measures were critical to the interpretation of the tenofovir (TFV)-disoproxil-fumarate/emtricitabine (TDF/FTC) PrEP trials. These measures are being incorporated into PrEP demonstration projects, but currently-available metrics in plasma, cells, hair or urine involve expensive and time-intensive mass-spectrometry (MS)-based methods. No point-of-care method to assess PrEP adherence in real-time has yet been implemented. Antibody-based tests allow for low-cost, easy-to-perform, point-of-care drug detection. In this study, we developed an antibody-based TFV immunoassay and evaluated its test characteristics among individuals taking TDF/FTC.MethodsWe synthesized possible immunogens based on TFV's molecular structure, injected rabbits with the conjugated derivatives, and bled them monthly for subsequent ELISA-testing for TFV-specific antibodies. We purified an antibody with specific TFV binding and created dose-response curves for ELISA-quantification. We then quantified TFV in urine from human participants not taking TDF/FTC and from individuals taking daily TDF/FTC 300 mg/200 mg for 7 days with a 7-day washout period using ELISA with this TFV-specific antibody. ELISA results were compared with the gold-standard test for TFV detection/quantification using liquid-chromatography-tandem-MS (LC-MS/MS).FindingsNone of the urine samples from 115 participants not taking TDF/FTC showed ELISA- reactivity, indicating 100% specificity (95% CI 97-100%) of the immunoassay. Among participants taking TDF/FTC, 67 of 70 samples positive by LC-MS/MS were positive by the ELISA-immunoassay for an estimated diagnostic sensitivity of 96% (95% CI 88-99%). The precision of the assay was high (coefficient of variationb15%). The rank correlation between ELISA and LC-MS/MS values in the 70 quantitative urine TFV levels positive by LC-MS/MS across a wide range of concentrations among participants on TDF/FTC was high (r = 0.96).InterpretationOur antibody-based immunoassay for measuring TFV in urine performed well compared to the gold-standard of LC-MS/MS among individuals taking TDF/FTC. A sensitive and specific immunoassay paves the way for real-time monitoring/feedback on recent adherence to TFV-based regimens, which should optimize interpretation and outcomes during PrEP and ART roll-out.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.